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ABSTRACT OF THE DISSERTATION
INVESTIGATIONS OF CELL-PENETRATING AND MEMBRANE-PORE FORMING
PEPTIDES
by
Rudramani Pokhrel
Florida International University, 2020
Miami, Florida
Professor Bernard S. Gerstman, Co-Major Professor
Professor Prem P. Chapagain, Co-Major Professor
Cell-penetrating and membrane-pore forming peptides are a class of membraneactive peptides. They are short sequence peptides having both hydrophilic and lipophilic
combinations of amino acids. These peptides can have contrast functional diversity.
Peptides encoded by viruses function as viroporins and play a critical role in viral
replication, propagation, and pathogenesis. One such peptide is the Ebola virus delta
peptide, which forms a pore in the host cell membrane. Another set of pore-forming
peptides are antimicrobial Lantibiotic peptides that may be useful for killing antibiotic
resistant bacteria by disrupting the bacterial membrane through two different possible
mechanisms. Not only can they form pores that disrupt the bacterial membrane,
Lantibiotics can also hinder the function of a bacterial membrane molecule, Lipid II, that
is essential for cell wall biosynthesis.
I performed Molecular Dynamics (MD) simulation to investigate the membrane
pore-forming mechanism of the Ebola virus delta peptide. I found that the Ebola virus delta
peptide forms a pentameric pore in the host cell membrane. The pore is selective for

vii

negatively charged ions, and the disulfide link between Cysteine 29 and 38 is essential for
stable and effective membrane-pore formation. Similarly, I studied Lipid II binding and
membrane-pore forming activity of several Lantibiotics: Nisin, Mutacin 1140,
Gallidermin, NAI107, and NVB302. The computational results from MD simulations
show that Nisin forms the most effective water channel in the bacterial membrane, but
Gallidermin has the best Lipid II binding profile. Mutacin 1140 also binds strongly with
Lipid II and forms an efficient water channel in the bacterial membrane. I also performed
MD computations on a variety of mutated peptides of Mutacin 1140 and the Ebola virus
delta peptides and investigated their water solubility, Lipid II binding, and membrane
insertion profile. These results provide insight into the possible antimicrobial peptides with
an optimized drug profile.
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1. INTRODUCTION
1.1 Cell-Penetrating and Membrane Pore-Forming Peptides
The membrane is a natural barrier that stabilizes and protects living cells by
separating the cells’ internal and external environments. It precisely controls the exchange
of water, ions, and other nutrients between a cell and the extracellular environments.
Though the thickness of a membrane is only about 5 nm 1, its structure and composition
are very complex and diverse throughout different species. For example, a mammalian
membrane is primarily composed of phospholipids, cholesterol, membrane proteins,
carbohydrates, and fatty acids 2, while the bacterial membrane is devoid of sterol and
typically is negatively charged 3. Despite these differences, the major components of both
kinds of the cell membrane are the phospholipids. These lipids have hydrophilic head
groups and hydrophobic alkyl chains4. The amphipathic nature of lipids enables them to
assemble into the membrane complex in water readily. The morphology of the complex is
either a lamellar bilayer or non-lamellar as in micelles5. In bilayer assemblies, hydrophilic
head groups are exposed on the inner and outer membrane surface, and the long lipid
molecules are aligned vertically (perpendicular to the membrane surface) so that the
hydrophobic alkyl chains are buried in the membrane core and not exposed to water. The
vertical alignment of the chains allows short amphipathic peptides to insert and penetrate
these lipid bilayers.
Membrane-active peptides are short-sequence proteins that may or may not have a
lytic effect on the cell membrane6. Most membrane-active peptides are amphipathic;
however, they differ in their mode of actions on mammalian membranes compared to

1

bacterial membranes7. The highly diverse class of membrane interacting peptides are
antimicrobial peptides (AMPs). In multicellular organisms, AMPs are essential for innate
immunity against invading pathogenic microorganisms8. The AMPs are positively charged
short peptides; hence they engage actively with the generally negatively charged bacterial
membrane. The amphipathic composition of amino acids provides solubility in both
aqueous solution and membrane environment8. Their usual activity involves creating
plasma membrane perturbation usually via membrane pore formation or membrane
permeabilization, which causes cell lysis in pathogens9-10. A unique subgroup of AMPs
produced by bacteria, called lantibiotics, hinders the cell wall synthesis of bacterial
membranes by trafficking molecules that are important for the synthesis process. In recent
studies, lantibiotics have shown great potential against the resistant-strains11-12. Because of
their

remarkable structural and functional diversity, AMPs offer a wide spectrum of

activity and make them promising candidates for therapeutic applications13.
Recently, a new class of peptides encoded mainly by RNA viruses has been
identified, which are critical for viral replication, propagation, and pathogenesis14. They
are usually called viroporins, and more recently, these proteins have also been found in
small DNA viruses14. They can alter the host cell membrane resulting in the disruption of
ionic gradient, membrane fusion, budding, and release of virions15. These viroporins
generally have at least one amphipathic alpha-helix and form oligomeric transmembrane
channels in the plasma membrane or endoplasmic reticulum of the host cell. Some
examples of viroporins are HIV-1 vpu, hepatitis C virus (HCV) p7 protein, and ebola virus
delta-peptides

15-17

. Since they are important for the viral life cycle, viroporins are

promising targets for clinical intervention18. There is another group of short peptides that
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can translocate through membrane bilayers without causing significant damage to
membrane integrity and hence they are important for intracellular drug delivery in
biological experiments. These are either arginine-rich peptides such as the TAT peptide or
lysine-rich amphipathic peptides such as Transportan19.
The method in which these peptides penetrate and disrupt the cell membrane has
been extensively explored experimentally over many decades and more recently using
computational molecular dynamics (MD) simulations. However, an understanding of the
mechanism at the molecular level is still lacking6, 20-21. Also, the interaction mechanisms
with the membrane of recently discovered peptides such as mutacin 1140 (MU1140) and
Ebola virus delta-peptides are largely unknown. It is important to understand the modes of
interaction of these peptides with cellular membranes so that we can devise inhibitors for
cytotoxic peptides such as viroporins to prevent viral infection, and also learn how to
modify these toxic peptides to selectively target cancer cells. On the other side, we would
also like to strengthen AMPs to fight against the threat of antibiotic-resistant strains of
bacteria.
My work focuses on two of the peptides highly worthy of investigation to address
the current challenges in human health: the EBOV delta peptide and Lantibiotics. By using
molecular dynamics simulation, for the first time, I have investigated the membrane poreforming mechanism of EBOV delta peptides, which may lead to the design and development
of targets for pore modulators and disruptors, and thus the ability to controll virus propagation.
Additionally, I have explored the bacterial killing mechanism of a few important lantibiotics,
e.g., Mutacin 1140, Nisin, etc. and probed their efficacy for lipid II binding and membrane pore
formation. My research also involves the computationally modeled hybrid peptides from the
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combination of MU1140 and EBOV delta peptide. I have investigated the water solubility and
membrane insertion profiles of these hybrid peptides alongside with wild-type MU1140 to
inform the peptide with the optimized antimicrobial profile. Such a detailed study at the atomic
level could facilitate the design and development of antiviral and antibacterial regimens.
1.1.1 Ebola Virus Delta Peptide
The Ebola virus (EBOV), a member of the Filoviridae family, causes a severe
hemorrhagic disease with an average current fatality rate of ~50 % in humans22. Of the five
Ebola species that are identified within the genus Ebolavirus, four cause Ebola virus
disease (EVD) in humans, while the fifth only causes a disease in nonhuman primates23.
The Zaire Ebolavirus species was responsible for the major 2013 EVD outbreak that
occurred in West Africa24-26. Ebola is especially dangerous because of a lack of effective
vaccines and chemotherapeutics27-28, and underscores that EVD remains a major challenge
in basic, translational, and clinical research. The elucidation of the molecular mechanisms
responsible for EBOV replication and pathogenesis is an important step in the development
of antiviral therapies.
Recent studies have shown that the Ebola virus delta peptide (Figure 1.1)29, a
partially conserved non-structural protein, can act as a viroporin and thus may be involved
in the pathology caused by EVD20,

30

. Viroporins are relatively small hydrophobic

transmembrane proteins that are encoded by a broad range of viruses15, 31-34, including
EBOV20, 30. The viroporin proteins homo-oligomerize in the host cell membrane to form
amphipathic pores that modify the properties of intracellular membranes15, 35. Importantly,
the viroporins have become novel drug targets34 because of their numerous vital roles in
the virus, such as membrane permeability36, ion flux, protein trafficking, and virion
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morphogenesis and release from host cells15. However, the molecular mechanisms of pore
formation and the functioning of the Ebola virus delta peptide viroporin are not well
understood.

Figure 1.1 The primary structure of the Ebola virus delta peptide and its 3D-structure
predicted by Phyre236. Color coding: basic residues (gray-blue), acidic residues (pink),
hydrophobic (white), hydrophilic (green), and glycosylated sugar (orange). The disulfide
bond between C-29 and C-38 is shown in yellow.
During the EVD, the delta peptide is produced from the cleavage of the carboxylterminal of the secreted glycoprotein (sGP)37-38. The 40-residue long delta peptide has a
variable 17 residue N-terminus (N-ter) and a conserved, 23 residue C-terminus (C-ter)20,
30

. The aromatic and basic amino acid rich motif, and the two cysteines at the C-ter of the

peptide, are conserved within all Ebola species, as well as in other pore forming peptides,
including the cytolytic peptide of the non-structural protein 4 of the rotavirus39. Two
aspects of the delta peptide are significant for its pore-forming ability20,

30

, i) an

amphipathic a-helical structural motif in the middle that drives the membrane activity of
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many pore-forming peptides15, 35, 40, (ii) the conserved pair of cysteine residues (Cys-29
and Cys-38) in the C-ter that can help to form a disulfide cross-linked hairpin amphipathic
structure that is similar to many membrane-permeabilizing antimicrobial peptides32. A
recent experimental study demonstrated the presence of the C-ter, disulfide cross-linked
hairpin structure for the membrane-permeabilizing activity41. The experimental study also
showed that the delta peptide forms smaller and more selective ion-permeable pores in a
synthetic lipid-bilayer.
1.1.2 Lantibiotics
In recent years, there has been an alarming rise in antibacterial resistance infections
caused by inappropriate use of antibiotics in humans and agricultural feed42-45. Antibiotic
resistance now accounts for higher medical costs, prolonged hospital stays, and increased
mortality46. Globally, there is a high incidence rate of hospital-acquired infections,
including infections by methicillin-resistant Staphylococcus aureus (MRSA) or multidrugresistant (pan-resistant) Gram-negative bacteria44, 47-48. Several studies warn that if there is
not a major advancement in antibiotics, there may be tens of millions of deaths annually
along with trillions of dollars of medical expenses due to antibiotic resistant infections by
the year 205049-50. Hence there is a dire need for the development of new antibiotics
utilizing novel modes of action. A unique class of peptides, lantibiotics are promising
candidates to engage in the fight against resistant strains of bacteria51-53.
Lantibiotics are ribosomally synthesized peptides that contain post-translationally
modified unusual amino acids, such as lanthionine (Lan), ß-methyl-lanthionine (Melan),
didehydroalanine (Dha), didehydrobutyrine (Dhb) and aminovinyl-cysteine (Avicys)52, 5455

(Figure 1.2). A thioether ring Lan (Ala-S-Ala) is formed when the ß-carbons of two
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alanine-like derivatives cross-linked via a sulfur atom. Likewise, Melan (Abu-S-Ala) is
formed between alanine and aminobutyric acid-like derivatives. On the other hand, AviCys
is decarboxylated Lan which is located at the last position of lantibiotic sequence. The post
translationally modified aminoacids Dha and Dhb are derived from dehydration of serine
and threonine residues in the precursor peptides56-57. The two main categories of high
activity lantibiotics, Type A and Type B, are distinguished by their biosynthesis pathways
and structures58. Type A lantibiotics are longer and more flexible than Type B, which
include nisin, MU1140, gallidermin and epidermin. The shorter, globular Type B
lantibiotics include mersacidin, cinnamycin, and duramycins59

Figure 1.2 The primary sequence of a lantibiotic, Gallidermin. It has four sulfur bridged
rings and first two rings serve as a lipid II binding moiety.
Lantibiotics are especially important in current antibiotic research because of their
efficacy against resistant Gram-positive bacterial strains that result from unique modes of
action. The first two rings of lantibiotics bind to the pyrophosphate of bacterial membrane
lipid II molecules and impede the critical functioning of lipid II in bacterial cell wall
biosynthesis. Lipid II has two binding moieties for antimicrobial peptides. One is the
peptide moiety that is the target for current clinical drugs, including vancomycin, and the
other moiety is the pyrophosphate group targeted by several lantibiotics60. The last two
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rings of lantibiotics can flip and insert into the bacteria membrane to form membrane pores
that disrupt the membrane homeostasis in bacteria61-62. The latter mode of action is
especially prominent for Class I lantibiotics because they have flexible hinge regions63-65.
These multiple modes of action to kill bacteria, especially targeting pyrophosphate of lipid
II lessens the frequency of development of resistant bacterial strains. Nevertheless, some
studies have reported that a few bacterial strains66-67 developed some resistance against
nisin via modifying their cell wall, forming biofilms, and expressing additional proteins.
To date, little is known about the molecular mechanisms or horizontal transfer of lantibiotic
resistance in comparison to resistance to current commercial antibiotics44, 50, 68.
Though nisin has been used in food as preservatives for more than 60 years, there
are no other lantibiotics in clinical usage. Several lantibiotics, such as MU1140 variants,
NAI-107, and NVB302 are currently in pre-clinical and clinical trials69. Experimental and
computational studies on nisin, MU1140 and gallidermin have provided information on
how they form functional membrane pores that can affect membrane permeability, but
there is need for atomic-scale investigation that investigates and compares the lipid II
binding, and stability of membrane-pores among these variants along with others63, 70-72 .
Information on the dynamics of pore formation will be especially valuable when coupled
with information on the peptide’s ability to interact with lipid II molecules. Such
information can be used to guide the design of more efficient lantibiotics with improved
anti-pathogenic properties and optimized therapeutic profile.
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1.2 Molecular Dynamics Computer Simulation
In most of my Ph.D. projects, I used molecular dynamics (MD)

73

computer

simulations to investigate conformational changes and recognition of biomolecules. The
original implication of MD simulation dates back to the 1960s, and nowadays it is
extensively exhausted

to a wide range of applications, including designing novel

materials, and drug discovery74

75

. By employing the basic laws of physics, the MD

simulation computes the interaction between atoms of biomolecules. The atoms of
biomolecules are represented as classical particles, and a potential energy function is used
to determine the interaction between these atoms. The potential energy function, generally
called force field, contains all possible interactions, as given in equation 1.2.1.
2

∑ K (r − r ) + ∑ K (θ − θ )

U total =

b

bonds

+

0

θ

2

0

angles

+

∑
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⎛A B ⎞
qi q j
⎜⎜ 12ij − 6ij ⎟⎟ + ∑
rij ⎠ electrostatic ε rij
van der Waals ⎝ rij

∑

i, j pairs

i, j pairs

(1.2.1)

The interaction energy is also represented in Figure 1. 3. The bonded interactions
include bond, angle, and dihedral term. A harmonic potential is applied to model the
covalent bond between two adjacent atoms. Similarly, the harmonic angular potential is
applied between three adjacent atom pairs. A dihedral term includes four covalently
bonded atoms in a linear sequence, where φ is the torsional angle of a central bond
connected to two covalent bonds. The dihedral interaction is periodic. Other bonded
harmonic interactions can include “improper terms” to describe four planar atoms' chirality
bound with covalent bonds. The non-bonded interactions comprise Van der Waal's energy
defined by Lenard Jones 6-12 potentials and the pairwise electrostatic interaction given by
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Coulomb's Law. A switching function is applied to smoothly cut off the non-bonded
interactions at user chosen cutoff distances to reduce the computational time and
complexity. In general, the cutoff distance of 12-14Å is used in MD simulations.

Figure 1. 3 Bonded interactions between atoms of a molecule.
For MD simulations, the starting position of atoms of a biomolecule is assigned
from the three-dimensional structure from the x-ray crystallography, NMR, cryo-EM, or
homology modeling. The Maxwell Boltzmann distribution of velocities is used to set initial
velocities of atoms at a given temperature. The gradient of potential energy function
described above gives the force of interaction between atoms and their acceleration. After
a user-defined short time step, the position and velocity of atoms are updated. The MD
trajectory contains time evolution data of position and velocity of each atom at every time
steps. Various methods and tools from statistical physics are used to investigate the
biomolecule's thermodynamic property from the MD trajectory. The obtained result can
be validated with experimental observables.

10

To capture the atomic vibrational events and for the stability of simulation systems,
MD time steps are limited to the femtosecond time scale. Hence it is impossible to observe
significant conformational changes in biomolecules which usually occurs in a time scale
above milliseconds. Though current advancement in Graphics Processing Units (GPUs)
has significantly accelerated the MD simulations time, only a few research groups have
been able to mark millisecond scale simulation provided with the most advanced
computational facilities. It is also nearly impossible for large biological systems to hit that
time scale as whole virus capsids or cells. Hence, computational scientists are constantly
aspiring for enhanced sampling simulation methods that employ non-equilibrium statistics
such as replica exchange MD, Steered MD, Umbrella Sampling, Targeted MD, CoarseGrained MD, etc. The current study used most of these techniques to study protein
dynamics, membrane protein interactions, and membrane-pore formation.
2. METHODS
2.1 All Atom Molecular Dynamics (AAMD) Simulation Protocol.
All-atom MD simulations were performed using the GPU version of NAMD2.1276
with the CHARMM36m force field77 employing periodic boundary condition in explicit
water solvent. The MD force field parameters for the lantibiotics’ unusual amino acids
Dha, Dhb, and Abu were taken from previous work on nisin by Turpin et al.78 The charge
of each system was neutralized by of NaCl and solvated with TIP3P water model. For
EBOV delta peptide membrane pore systems, 0.25 mM concentration of NaCl was used to
increase the ion flux events. For

all other simulations it was 0.15mM to mimic the
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biophysical conditions. The simulation systems without membrane were generated using
CHARMM-GUI solution builder while for the membrane systems CHARMM-GUI
membrane builder web server was used79. For the delta peptide membrane systems, I used
asymmetric membrane containing various lipids: POPC, POPE, POPS, POPI, PSM and
CHOL with 41:8:4:4:23:20 ratios in the outer leaflet and 11:37:16:10:5:21 ratios in the
inner leaflet, which are in accordance with the asymmetric complexity of the plasma
membrane4, 80-83. The bacterial lipid bilayer for lantibiotics contains POPE and POPG
lipids in the ratio of 1:3 to represent the membrane of Gram-positive bacteria84.
Systems without membrane were minimization for at least 10,000 steps and
equilibrated for 100ps. The minimization and equilibration dynamics of the membrane
system were performed following the CHARMM 6-step protocol. Periodic boundary
conditions were employed in all simulations. The long-range electrostatic interactions were
treated using the particle mesh Ewald (PME) method85. The Particle Mesh Ewald (PME)86
method was used to calculate the long-range electrostatic interaction and the SHAKE
algorithm87 was used to constrain hydrogen atoms. A Nose-Hoover Langevinpiston method was used with a piston period of 50 fs and a decay of 25 fs to control the
pressure. All simulations were run at 300 K temperature with Langevin temperature
coupling and a friction coefficient of 1 ps−1. For calculations of hydrogen bonds, the cutoff distance and cut-off angle were 3.5 Å and 30° respectively. The visualization tool
VMD88 was used to visualize the trajectories and render the pictures.
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2.2 Steered Molecular Dynamics (SMD)
The SMD simulation mimics the optical tweezer or atomic force microscopy
experiments on shorter time scales89. In a molecule, one group of atoms are fixed in a
position, and center of mass of other group is pulled in a particular direction. The harmonic
constrained with force k is applied to the center of mass of SMD atoms to move with
velocity v in the direction 𝑛#⃗. As a result, the potential applied to the system is:
!
U(𝑟⃗1(t),𝑟⃗2(t),…,t) = " k [(vt - (𝑅#⃗(t)-𝑅#⃗0).𝑛#⃗]2

𝑅#⃗0 and 𝑅#⃗(t) are the center of mass of SMD atoms at initial and at time t. t = Ns*dt, where
Ns is the number of elapsed time steps, and dt is the size of a time step. The variable n
####⃗ is a normalized vector in pulling direction76. For SMD, the dummy atom is
with arrow (𝑛)
attached to the COM of SMD atoms via a virtual spring of force constant k.
To break disulfide cross-links between C29 and C38 and flip the C-terminal
anchorage of EBOV delta peptide, I performed SMD simulation with the plasma membrane
in explicit water. I pulled the last four heavy atoms of the Arg-39 sidechain along the zaxis at a constant velocity of 1 Å/ns for 20 ns with a spring of constant k = 5 kCal/mol/
Å2. I also performed the SMD simulations for six hybrid peptides along with MU1140 to
explore the membrane insertion profile. For six hybrid models, I pulled the three-carbon
alpha atoms of amino acids Glu33, Lys34, and Leu35. For wild-type (WT) I pulled the
carbon alpha of Tyr20 and Ala21 along the negative z-axis at a constant velocity of 0.5
Å/ns for 100 ns. The spring constant was k = 5 kCal/mol/ Å2. With additional constrained
in fixed and SMD atoms, simulations follow the same protocol as explained in section 2.1.
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2.3 Umbrella Sampling (US)
Umbrella sampling is an enhanced sampling method used to estimate the relative
free energy of different conformational dynamics along the reaction coordinates90. It
consists of running separate windows of the reaction coordinates parallelly. For each
independent window, the system is constrained to sample a narrow phase space along the
reaction coordinate to ensure potential energy distribution overlap between adjacent
windows. A harmonic or adaptive bias potential is applied to each window91. After the
simulations, a post-processing integration methods like weighted histogram analysis
method (WHAM)92, are used to estimate the unbiased free energy by the umbrella
integration. The bias potential applied to the system in a window is:
wi(𝜁) =

!
"

𝐾(𝜁 − 𝜁# )"

Where 𝜁# is reference coordinate point, and k is force constant.
Then the total energy of the system could be written as:
E = Eunbias + wi(𝜁)
I used US method to estimate the free energy of flipping the delta peptide anchored tail out
of the membrane. From SMD trajectory, I made 20 windows of 1 Å each along the z-axis
from z = -13 to z = 7 Å. Similarly, for membrane insertion energy landscape of hybrid
peptides, I took 25 different windows from SMD trajectories of each seven systems from
z = 19 Å to z = -29 Å each 2 Å distance apart. For both systems, the reaction coordinate
was chosen as the distance between the center-of-mass of the pulled atoms relative to the
center-of-mass of the membrane along the z-axis. Each window was then run for 10 ns of
NPT simulation after quick minimization and equilibration. The force constant for
harmonic bias potential was 5 kCal/mol/ Å2.
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3. MEMBRANE PORE FORMATION AND ION SELECTIVITY OF THE EBOLA
VIRUS DELTA PEPTIDE
This chapter was published in 2019: R. Pokhrel, E. Pavadai, B.S. Gerstman, P.P.
Chapagain, Membrane pore formation and ion selectivity of the Ebola virus delta
peptide, Phys Chem Chem Phys, 21 (2019) 5578-5585.
To understand the mechanism of stable pore formation and ion selectivity of the
EBOV delta peptide, I modeled the delta peptide viroporin in different oligomeric states,
including tetrameric, pentameric, and hexameric forms. I then performed extensive allatom molecular dynamics (MD) simulations in an explicit membrane environment to
optimize these oligomeric structures and investigate the dynamics of their pore-forming
mechanisms. I analyzed the pore properties for the different oligomers in the lipid-bilayer,
including the energies and arrangements of the oligomers, pore radius, and water and ion
permeation through the pores. Our study provides helpful information to better understand
the stable viroporin pore-forming mechanism of filoviruses and such structural studies may
not only assist in the design and development of antiviral drugs but also have relevance to
pore-forming mechanisms of antimicrobial peptides.93
3.1 Construction of the Transmembrane Assembly
The primary structure of the 40 residue EBOV delta peptide was obtained from He
et al.20 (Figure 1.1), and its secondary structure was predicted and modeled using the
protein homology/analogy recognition software

Phyre294

(Fig.

S1,

Supplementary

Information29). The tetramer, pentamer, and hexamer models of the delta peptide pore
were built by placing them symmetrically so that their pore diameters were about 10 Å and
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positively charged residues faced inwards to the pore channel (Fig. 3.1) as suggested by
He et al.20 and Gallaher et. al.30 In addition, Thr-5 and Thr-9 were O-glycosylated and a
disulfide bridge was added between C-ter Cys-29 and Cys-38. To understand the role of
the disulfide-bond in pore stability and ion flux, I also built pentamer and hexamer pore
models without the disulfide bond (reduced pore model). In total, I investigated five
different pore models: tetramer, pentamer, hexamer with Cys29-Cys38 disulfide bonds,
and pentamer and hexamer pores without the disulfide bond.
Each of the pore models were placed in the lipid bilayer using the CHARMM-GUI
membrane builder79. The charge of each system was neutralized by 0.25 mM concentration
of NaCl and solvated with TIP3P water model. The asymmetric membrane contains various
lipids: POPC, POPE, POPS, POPI, PSM and CHOL with 41:8:4:4:23:20 ratios in the outer
leaflet and 11:37:16:10:5:21 ratios in the inner leaflet, which are in accordance with the
asymmetric complexity of the plasma membrane4, 80-83. For each system, the glycosylated
N-ter of the peptides were placed towards the lower, inner leaflet of the plasma membrane
bilayer (Figure 3.1).

Figure 3.1 The initial structure of the delta peptide pore model for (a) tetramer (b) pentamer
(c) hexamer. The N-ter of the peptides are placed at the inner surface of the membrane,
which is at the bottom of the diagram. Peptides are shown by ribbon depiction. Color
coding: basic residues-blue-gray, acidic residues-purple, membrane-transparent light blue
cyan colors.
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3.2 Delta-Peptide Assembly and Dynamics
I constructed pores with symmetric placement of four, five, or six delta peptides,
according to the orientation of transmembrane amino acids in proposed models from
previous studies20, 30 in the lipid membrane bilayer. The C-ter basic residues (gray-blue at
the top in Figure 3.1), Lys-21, Lys-28, Lys-35, and Arg-39 are facing towards the central
channel of the pore to provide ion selectivity for chloride ions. In addition, the position of
these basic residues in the pores indicates that they can provide a smooth path for chloride
ions flux30. In contrast, the hydrophobic residues in the middle of the peptide are facing
outwards into the hydrophobic middle of the plasma membrane, facilitating pore insertion
into the plasma membrane and providing stability to the pore. The Glu-33 residue is at the
C-ter, which can hinder the flux of chloride ions from the C-terminal, suggesting that it can
act as a gate keeper to regulate ion flux and provide the unidirectional nature of the pores
from N-ter to C-ter. The assembly of the pore models suggests that they can pump out
water and chloride ions from animal cells, consistent with the EVD symptoms of fever,
weakness and multi-organ failure characterized by severe fluid loss and electrolytic
imbalance17, 20, 30, 41.
To investigate the structural and dynamical properties of the different EBOV delta
peptide pore formations, I performed >500 ns all-atom, explicit solvent MD simulations in
a lipid-bilayer for all three pore structural models that contain the disulfide bond: tetramer,
pentamer, and hexamer. The simulated systems and the timescales are listed in Table S1
(Supplementary Information)29. I quantitatively analyzed the stability of the pore structures
in a variety of ways. I computed the root mean square deviations (RMSD) summed over
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all of the Ca atoms of the pore structures relative to their initial positions (i.e. initial frame
of MD as the reference structure) as a function of simulation time as shown in Figure
3.2a. All pore models reached an apparent equilibrium after 200 ns with an RMSD
compared to their initial structures of approximately 4.5 Å. Of the three models, the
pentamer model showed more stabilized RMSD values. To track this behavior at longer
timescales, I extended the pentamer simulation to 1.1 µs and plotted the RMSD in Fig. S2
(Supplementary Information)29. I observed a slight increase in the RMSD but as discussed
later, the pore structure is further stabilized.
The flexibility of the pore structures was further analyzed by means of the root
mean square fluctuation (RMSF) determined from the last 100 ns of the MD simulation
trajectories. The results for the Cα of each residue are displayed in Figure 3.2b. The RMSF
shows that the pentamer is the most stable and the tetramer has the largest movement of its
Cα atoms, signifying that there is a considerable motion between the peptides in the
tetramer. This is in good agreement with the RMSD analysis. The analysis of the RMSD
and RMSF shows that the pentamer pore is a more stable viroporin compared to the
tetramer and hexamer pores.
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Figure 3.2 For tetrameric, pentameric, and hexameric pores: (a) Time evolution of the root
mean square deviation (RMSD) from the initial position averaged over all Cα, and (b) root
mean square fluctuation (RMSF) in the position of each Cα averaged over the last 100 ns.
To further understand the conformational changes of the peptides, in Figure 3.3 I
compare the initial structures of the tetramer, pentamer, and hexamer pores to a snapshot
taken at 500 ns. In all cases, the pore structure remains intact but changes in the
arrangement of individual peptides can be seen, especially in the tetramer and hexamer. In
addition, visual inspection of the initial structure compared with its final structure shows
that the tetramer and hexamer pores have lost more of their initial symmetric arrangement
and become more disordered compared to the pentamer pore.
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Figure 3.3 Comparison of initial pore structure to pore structure at 500 ns. The top and
middle row are end views looking from outside the membrane and the bottom is a side
view. Columns: (a) tetramer (b) pentamer and (c) hexamer. In the end views, Arg-39 is
shown as gray-blue color.
3.3 Hydrogen Bond and Interaction Energy Profiles in Various Pore Assemblies
To further quantify the stability of the different pore models, I analyzed non-bonded
interactions: H-bonds, electrostatic, and van der Waals interaction energies, as shown in
Figure 3.4. The inter-helical interaction energy was calculated for all peptide pairs for each
pore model and then divided by the number of peptides to obtain the average energy. The
averaged electrostatic energy is approximately the same for all oligomers after 300 ns of
simulation time. However, the van der Waals energy plot (Figure 3.4b) clearly shows the
tetramer has weaker van der Waals interactions than the pentamer and hexamer. Figure
3.4c shows the average number of hydrogen bonds for peptide pairs, normalized in a
similar way as for the interaction energy calculations. In the beginning of the simulations,
all pore models show a similar trend, but at the end of the simulations, the pentamer has a
larger number of hydrogen bonds (three) compared to the tetramer and hexamer (two). The
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results displayed in Figure 3.4b and Figure 3.4c indicate that peptide arrangement
symmetry and inter-peptide distance play key roles in the stability of the pentamer pore
and facilitate the formation of more non-bonded contacts between peptides compared to
the tetramer and hexamer pore formations.

Figure 3.4 Averaged non-bonded pore interactions: (a) electrostatic, (b) van der Waals, and
(c) H-bonds.
3.4 Pore Size, Water and Ion Fluxes
To gain further insight into delta peptide pore stability, the radius of each pore was
averaged over the last 300 ns of the simulation trajectories using the HOLE program95.
This program has been extensively used to study the size of protein channels96-98 and
computes the transverse radius of pores based on the van der Waals radius of the atoms.
Figure 3.5a shows the average pore volume, calculated using HOLE. In Figure 3.5b, I
display the pore radius along the long z-axis of the channels during the final 300 ns along
with the standard deviation. The mid-point of the membrane is chosen to define z=0. In all
three pores, the average radius of the pores is greater than 2.5 Å, giving a diameter greater
than 5 Å, which is significantly larger than the diameter of a water molecule, 2.8 Å.
Though it is composed of the fewest number of peptides, the tetramer displays a relatively
large pore size because of the structural distortion of the peptide arrangement during the
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simulation. The pentamer shows a smaller variation in its average pore size along the length
of the channel and smaller standard deviation than the tetramer or hexamer.
In addition, Figure 3.5b shows that for all pore profiles, the N-ter mouth of the pore
at z = -18 has a radius of approximately 4 Å, which is wide enough for three water
molecules. In contrast, the C-ter mouth of all of the pores at z = +18 have constricted pores
of radius 3 Å. This difference in the pore size suggests that the pores allow water and ions
to flow from N-ter to C-ter. The tetramer and hexamer have greater fluctuations in their
pore radius at both ends of the pores than the pentamer, as shown in Figure 3.5 and Movie
S1(Supplementary Information)29, showing that the pentamer pore is more stable. In the
Movie, sections that are too narrow to pass any water molecules are colored red, green if
they allow one water molecule to pass, and blue if they are wide enough to pass two or
more water molecules. The C-ter region containing the acidic residue Glu-33 of the
hexameric pore contains more frames having red sections than the pentamer and tetramer.
The tetramer has wider bulging in the middle region of the pore. In contrast, the pentameric
pore remains well formed throughout the simulation. To track the pore stability of the
pentamer model at longer timescales, I extended the simulation for this system to 1.1 µs.
Comparison of the pore radius calculated for 300 to 500 ns and 900 to 1100 ns shows a
significantly reduced fluctuation, indicating a stabilized pore as shown in Fig. S3
(Supplementary Information)29. In addition, Fig. S3 also shows narrowing of the pore
radius near the top of the channel. The pore is still able to pass Cl- ions but the narrowing
at one end may help in ion selectivity.
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Figure 3.5 a) Volumetric map of the pores for various oligomeric assemblies. b) Average
radius of pores calculated from the last 300 ns of the MD simulations. The volumetric maps
and the radius profiles are colored the same way in a) and b).
To explore the pore permeability, the relative density of water, and chloride and
sodium ions through the pore were analyzed with the VMD Density Profile Tool99. The
density is the one-dimensional density calculated along the z-axis of the pores and averaged
over the last 300 ns of the MD trajectories. This analysis shows the presence and absence
of water and ions in the pore and is a measure of their permeability. Figure 3.6 shows the
relative number densities along the pore, with z =0 at the center of the pore. As shown in
Figure 3.6a and Figure 3.6b, all three oligomers are capable of passing water and chloride
ions, but in Figure 3.6c the density of sodium ions is zero around the center for all three
pores. This result clearly suggests that the pores selectively pass water and chloride ions.
The presence of lysine and arginine basic residues in the pores (Figure 1.1 and Figure 3.1)
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facilitate the ion permeation. The chloride ion permeation in the pentameric pore is shown
in Movie S229.

Figure 3.6 Along the length (z-axis) of the pores, the relative density profile of: (a) water
(b) chloride (c) sodium
The density profile indicates a significant presence of chloride ions within the
pores; however, the density analysis is not a complete measure of the flux of ions through
the pores. To understand which of the pores is most effective for chloride ion transport, the
passage of chloride ions from the inner leaflet to the outer leaflet (Figure 3.7: OUT) and
vice versa (Figure 3.7: IN) are plotted in Figure 3.7. In Figure 3.7, the 500 ns MD
simulation is split into 100ns bins. The number of IN and OUT chloride ion flux is plotted
for each time bin for each pore. Figure 3.7 shows that the hexamer pore has the largest
number of chloride ions traveling through in both directions (35 OUT, 27 IN). This may
be due to distortions of the hexamer pore such as reorientation of the basic Arg-39 residue
in the C-ter tail. This distortion of the hexamer pore may be destabilizing and at later times
lead to the disruption of the pore. In contrast, though the pentameric pore shows a smaller
flux of chloride ions (13 OUT, 10 IN), the pentamer pore retains its symmetric structure
throughout the simulation with little sign of distortion or disruption. The tetramer pore
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displays the least usefulness with a reversed chloride ion flux (5 OUT, 13 IN) and high
distortion and destabilizing fluctuations (Figure 3.2 and Figure 3.3).

Figure 3.7 Flux of Cl- ions through the pores for (a) tetramer (b) pentamer (c) hexamer.
The hexamer allows the largest flux.
3. 5 Role of the Disulfide-Bond in Pore Formation and Ions Flux
The presence of conserved disulfide-bonds in a wide range of amphiphilic
antimicrobial peptides is important for membrane permeation and pore-forming
activities32. Recent experimental study demonstrated that the formation of the conserved
disulfide-bond between the C-ter Cys-29 and Cys-38 in the EBOV delta peptide is essential
for its membrane permeability and pore formation20, 41. To better understand the role of the
conserved disulfide-bond in pore formation and permeability, I performed MD simulations
with the pentamer and hexamer pores, but constructed of peptides without the disulfide
bond (reduced state of Cys-29 and Cys-38 residues), and compared the results to the
pentamer and hexamer pores that have strong peptide disulfide-bonds. I did not study the
tetramer pore under the condition of no disulfide bonds since it is the least stable oligomer
with the lowest pore forming capability.
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First, I determined if the absence of the disulfide bond in a peptide could cause the
C-ter tail (residues 32-40) to flip out of the membrane and into the aqueous environment.
For a peptide without the disulfide bond, I performed Steered Molecular Dynamics (SMD)
simulations to calculate the relative free energy of the C-ter tail if it remains in the
membrane compared to if it is exposed to solvent. The change in position of the tail from
inside to outside the membrane bilayer is shown in Figure 3.8a. The free energy curve
(Figure 3.8b) for the pulling that flips the C-ter out of the lipid bilayer shows that the
configuration of the tail has a lower free energy when it was flipped out of the membrane
(z>20 Å) and exposed to solvent.

Figure 3.8 For peptides without the disulfide bond in the C-ter region: (a) Initial and final
configuration of SMD simulation of a single delta peptide in which the Arg-39 side chain
is pulled at constant velocity out of the membrane. (b) Free Energy of the peptide without
the disulfide bond as a function of the C-ter tail relative to the surface of the membrane
(z=0) (c) Pentamer pore model, (d) Hexamer pore model, in the bilayer membrane system.
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To determine how pore stability and permeability would be affected in the absence
of the peptide disulfide bonds, I performed MD simulations with pentamer and hexamer
pore models composed of peptides without disulfide bonds that have their C-ter tail
exposed to water (Figure 3.8c and Figure 3.8d) as the initial structure. As shown in Figure
3.9, the pores without the peptide disulfide-bonds show a much larger RMSD compared to
the pores with peptide disulfide-bonds, indicating that the presence of peptide disulfidebonds stabilize the pores. In addition, the analysis of the pore structures at different
simulation times shows that the pores composed of peptides without disulfide bonds
display significantly more structural distortion from their initial symmetric structure than
pores with peptides containing disulfide bonds (Figure 3.3), especially for the pentamer.

Figure 3.9 For the pentamer pore and the hexamer pore, comparison of the RMSD for the
peptides’ Cα with and without peptide disulfide bonds. Here, curves for the peptides
without the disulfide bond are labeled as WO-DISU and with the disulfide bond are labeled
as W-DISU
In addition to the RMSD analysis for the pores without peptide disulfide bonds, the
average pore radius, the profiles of chloride ion density and flux of reduced pore models,
were also computed and compared to that of pores with peptide disulfide bonds models.
As shown in Figure 3.10, the pore-radius in the central region has decreased for the pores
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without disulfide bonds in both pentamer and hexamer models. The pentamer pore without
disulfide bonds is still stable but the hexamer pore is significantly distorted in the absence
of disulfide bonds, as reflected by the deviation in the pore radius in Figure 3.10b. The
much wider fluctuations of the end residues of the pores without peptide disulfide bonds
reflect the decreased stability of the pore. This is further supported by a reduction in
chloride ion density and flux for the pores without peptide disulfide bonds in Figure 3.10.
Overall, the results show that the peptide disulfide-bond is essential to maintaining the
structural integrity of the pore and the flux of chloride ions, which is consistent with the
experimental suggestions20, 41.

Figure 3.10 a) Average pore radius from the last 300 ns of the MD simulation for the
pentamer and (b) hexamer, composed of peptides with and without disulfide bonds. The
shaded region shows the standard deviation of pore radius. The much wider fluctuations of
the end residues at the C-ter (z>20 Å) of the pores without peptide disulfide bonds reflects
the decreased stability of the pore. c) Comparison of average density of chloride atoms
along the pore for pores with and without peptide disulfide bonds for pentamer and (d)
hexamer. For both the pentamer and the hexamer, fewer chloride ions are found in the
pores without peptide disulfide bonds.
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LIPID

II

BINDING

AND

TRANSMEMBRANE

PROPERTIES

OF

ANTIMICROBIAL LANTIBIOTICS.
4.1 Molecular Mechanisms of Pore Formation and Membrane Disruption by the
Antimicrobial Lantibiotic Peptide Mutacin 1140
This chapter was published in 2020: R. Pokhrel, N. Bhattarai, P. Baral, B.S. Gerstman, J.H.
Park, M. Handfield, P.P. Chapagain, Molecular mechanisms of pore formation and
membrane disruption by the antimicrobial lantibiotic peptide Mutacin 1140, Phys Chem
Chem Phys, 21 (2019) 12530-12539.
In this work, I explored the potential mechanism of membrane pore formation by
performing molecular dynamics (MD) simulations of the MU1140-lipid II complex in the
bacterial membrane. Despite significant structural/sequence differences between the nisin
and MU1140 C-terminal tails, our results show that MU1140-lipid II complexes are able
to form functional, water permeating membrane pores. These investigations, for the first
time, provide an atomistic level insight into a novel mode of action for MU1140 that can
be exploited to develop optimized peptide variants with improved antimicrobial properties
and therapeutic profile.
4.1.1 Structural Comparison of MU1140 and Nisin
The NMR structure of the nisin-lipid II complex (PDB ID 1wco) was used as a
template to model the MU1140-lipid II complex (Figure 4.1), preserving the structure of
the pyrophosphate binding cage and the lantibiotic-lipid II interactions. With the target
being the pyrophosphate moiety, a dipeptide (Ala, Glu) was used for the peptide moiety
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and a longer bactoprenol tail was used that provided a stable anchorage during membranelipid II simulation. As with other lantibiotics chains, MU1140 contains unsaturated amino
acid residues dehydroalanine (Dha), dehydrobutyrine (Dhb), Aminobutyric acid (Abu), and
a C-terminal aminovinyl-D- cysteine (AviCys). It contains thioether rings connecting two
amino acids by a sulfur bridge, with Ala-S-Ala as the lanthionine derivative (Lan) and AbuS-Ala as the 3-methyl-lanthionine (MeLan) derivative. Conserved disulfide-bonds are
found in a wide range of amphiphilic antimicrobial peptides and viroporins, and are
important for membrane insertion and their pore-forming29, 100-101. In Figure 4.1, I compare
the sequence and structure of the nisin and MU1140 chains. Compared to the 34-residue
nisin, MU1140 is shorter, with only 21 amino acids. Nisin contains five thioether rings,
whereas MU1140 contains three thioether rings and a fourth ring formed by heteroatoms
at the C-terminal tail (Figure 4.1a, b).
Nisin has three Lys residues giving a net +3 charge (excluding N-terminus group).
In contrast, MU1140 contains a net +2 charge due to two basic amino acids Lys and Arg.
The anionic pyrophosphate moiety of lipid II with a net -2 charge provides the binding
target for the cationic MU1140. The hydrophilic head group of lipid II consists of two sugar
linked rings N-acetylglucosamine (GlcNAc), N-acetylmuramic acid (MurNAc), and
pentapeptides connected to MurNAc60, 102-103. The hydrophobic tail, bactoprenol is linked
to MurNac via pyrophosphate moiety. The lipid II binding thioether rings in nisin and
MU1140 (positions 3-11) are nearly identical, with only one amino acid difference (Ile vs.
Trp in position 4). Therefore, I used the structure of the nisin-lipid II complex (PDB ID
1wco) as a template for modeling the MU1140-lipid II complex, preserving the structure
of the pyrophosphate binding cage and the lantibiotic-lipid II interactions. The NMR
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structure of the nisin-lipid II61 complex is shown in Figure 4.1c and our model for the
MU1140-lipid II complex (energy minimized and equilibrated structure) is shown in Figure
4.1d.

Figure 4.1 Schematic representation of amino acid sequences of (a) nisin and (b) MU1140
chains. The NMR structure of (c) the nisin-lipid II complex61 and d) the modeled structure
of the MU1140-lipid II complex. The lantibiotic chains are shown in blue and lipid-II in
orange. The phosphate and oxygen atoms in the pyrophosphate moiety are highlighted in
gray and red respectively.
4.1.2 MU1140 Interactions with The Membrane Surface and Lipid II
To investigate the interactions of MU1140 chain with the membrane surface when
it is bound with lipid II in the membrane, I placed the MU1140-lipid II complex in the
membrane in such a way that the MU1140 chain lies horizontally on the outer surface of
the lipid bilayer, and the lipid II is inserted into the membrane, aligned parallel with other
lipids in the lipid bilayer (Figure 4.2a). The MU1140-membrane surface interactions are
relevant not only for its lipid II trafficking mechanism but also for the initial phase of the
peptide insertion into the membrane. I performed a 500-ns simulation of the complex in
the bacterial membrane composed of POPE and POPG in the ratio of 1:3.
I observed that the MU1140-lipid II complex remained intact throughout the
simulation, with strong interactions between MU1140 and the pyrophosphate moiety of
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lipid II. At the end of the 500-ns simulation, residues in the third thioether ring as well as
the C-terminal segment show partial insertion into the membrane bilayer (Figure 4.2a). In
Figure 4.2b, I plot the percentage of time during the MD simulation that major amino acids
in MU1140 form hydrogen bonds with the membrane as well as with lipid II (inset).
The MU1140 cationic side chain of Lys2 makes the major salt-bridge interaction
and the backbone NH groups of Phe1 and Lys2 provide strong hydrogen bonding with the
pyrophosphate group in lipid II (Figure 4.2b, right). As displayed in Figure 4.2c, MU1140
makes approximately three salt-bridge or hydrogen bonds interactions with lipid II
throughout the simulation. In addition, the bar graph for the MU1140-membrane hydrogen
bond in Figure 4.2b shows that MU1140 is able to strongly interact with the bacterial
membrane surface through significant hydrogen bonding. The major MU1140-membrane
hydrogen bond contribution comes from the MU1140 Arg13, followed by hetero-group
(AviCys) at the C-terminal tail and the backbone interactions of Tyr20. Overall, MU1140
makes about 12 hydrogen bonds on average with the membrane, as shown in Figure 4.2c.
In Figure 4.2d, I plotted the number of MU1140 contacts with lipid II within 3.5 Å.
MU1140 has a nearly constant number of interactions with POPE throughout the
simulation, whereas interactions with POPG shows slight increase after 200 ns.
As a control, I performed a separate simulation for the MU1140 chain on the
membrane surface while it is not complexed with lipid II. As shown in Fig. S1
(Supplementary Information )72, the MU1140 chain interacts with the membrane surface
but the partial insertion of the hydrophobic groups is not as pronounced as in MU1140
complexed with lipid II (Figure 4.2a). This suggests that the lipid II interactions in the
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pyrophosphate moiety allows the MU1140 chain to stabilize on the membrane surface and
facilitate membrane insertion.

Figure 4.2 (a) MU1140-lipid II complex in the membrane at 0 ns and 500 ns. MU1140 is
colored in by atom names, lipid II in orange, POPE in green, and POPG in gray. The
phosphorous atoms in the lipid headgroups are shown as spheres. (b) Percentage hydrogen
bonds between MU1140 and membrane as well as between MU1140 and lipid II (inset).
The % H-bond between MU1140 and lipid II are colored as, green: sidechain (SC), blue:
backbone NH group, and red: backbone CO group. Important MU1140 residues
participating in hydrogen bonding with lipid II are highlighted (right). c) Number of
hydrogen bonds of MU1140 with lipid II as well as with other lipids in the membrane as a
function of time. d) Number of lipid contacts with MU1140 as a function of time.
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4.1.3 Membrane Insertion of MU1140
A net cationic charge and a high fraction of the hydrophobic residues are two
common features of antimicrobial peptides (AMPs)104 and the hydrophobicity can allow
the peptide chain to insert into the membrane. MU1140’s close analogs, nisin and
gallidermin are both shown to form membrane pores105-106,107. Based on the similarities of
lipid II binding and the peptide composition with respect to nisin, epidermin, and
gallidermin, I conjectured that MU1140 can also form functional membrane pores. The
observation of peptide insertion in an all-atom computational model is difficult due to
temporal limitations of unbiased MD simulations. A 500-ns of detailed all-atom simulation
with full-length lipids allowed only a partial insertion of MU1140. To facilitate the
membrane insertion in reasonable computational timescales, I used a highly mobile
membrane-mimetic (HMMM) model108. The HMMM membrane model uses lipids with
shortened tails, floating on a layer of 1,1-dichloroethane (DCLE) representing the
hydrophobic inner core of the lipid bilayer. The fluidity of the system allows significantly
enhanced lipid diffusion that can provide unbiased lipid-binding of the protein well under
a microsecond. With the MU1140 chain aligned along the membrane surface (Figure 4.3a)
and the lipid II aligned parallel to the lipids, I performed a production run for 1.3 µs. Figure
4.3a shows the configuration of the complex in the beginning of the simulation (left panel)
and after 1 µs of simulation (right panel). Figure 4.3b shows the vertical distance (z-axis)
between Tyr20 and the center-of-mass of the lipid bilayer (representing the lipid bilayer’s
mid-point). After about 800 ns, the MU1140 chain begins to insert into the membrane and
by around 1 µs, most of the chain that is not interacting with the lipid II pyrophosphate
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cage is in the transmembrane region, as can be seen in Figure 4.3a (right) and the decreasing
distance from the lipid bilayer’s mid-point in Figure 4.3b. These results show that the
MU1140 chain prefers the hydrophobic transmembrane region compared to the outer
surface of the membrane.

Figure 4.3 a) Insertion of MU1140 into the HMMM membrane. For clarity, DCLE
molecules in the transmembrane region are not shown. b) Distance between the Tyr20 of
MU1140 and the center-of-mass (com) of the lipid bilayer (membrane mid-point).
4.1.4 Membrane Pore Formation and Water Permeation by MU1140
After confirming that the hydrophobic transmembrane region is a favorable
environment for the MU1140 chain, I investigated its pore forming ability. While insertion
is greatly facilitated by the HMMM membrane, the inserted MU1140 chain is indifferent
towards aligning in any specific orientation because of the fluidity of the transmembrane
DCLE that does not restrict the peptide chain to a vertical orientation as the full-length
lipids would. Therefore, investigation of the pore formation requires a bilayer with fulllength lipids. One way to set this up is to wait for a random even that vertically orients the
MU1140 chain in the HMMM membrane and then add the lipid tails. To expedite this
process, I set-up MU1140-lipid II complex in a conventional lipid bilayer with full-length
lipids but with the MU1140 already inserted and aligned vertically in the transmembrane
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region. I note that use of enhanced sampling methods such as accelerated molecular
dynamics may allow investigations of membrane insertion without having to reset the
system.
Figure 4.4a shows the initial configuration of the MU1140-lipid II complex in the
bacterial membrane composed of POPE and POPG in the 1:3 ratio. I performed a 500-ns
simulation for the system and observed a significant water permeation even with a single
complex of MU1140 and lipid II. Figure 4.4b shows a representative frame at the end of
the 500-ns simulation which shows water molecules along the MU1140 chain in the
transmembrane region.

Figure 4.4 MU1140-lipid II complex in a bacterial membrane: a) Initial configuration of
the complex and b) a configuration at the end of 500-ns simulation. The phosphorus atoms
of POPE are highlighted as green spheres and that of POPG as gray sphere. The water
molecules within 4 Å of the peptide are highlighted as red spheres.
Before the simulation began, only the N-terminal part of the peptide is exposed to
water on the outside of the bacterial membrane and the C-terminal is buried in the
transmembrane region as shown in Figure 4.4. Within a 100-ns, the lower end of MU1140
inside the membrane is in contact with water molecules below the membrane (intracellular
space). Despite having a significantly shorter chain compared to nisin, MU1140 is able to
span the transmembrane region and create a channel for water permeation. As with
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gallidermin that also harbors a shorter chain, the water permeation and pore formation by
MU1140 likely correlates with the membrane thickness107. The bactoprenol tail of lipid II
has no particular preference in its orientation and is quite flexible in the transmembrane
region. Although lipid II interactions may facilitate membrane insertion of MU1140,
simulations of MU1140 chain (not complexed with lipid II) in the transmembrane region
showed similar water permeation behavior (Fig. S2)72.
4.1.5 Single-File Water Permeation
To explore the mechanism of water permeation, I examined the residues and the
groups involved in interactions with water. I created a list of all water molecules that come
within 3.5 Å of peptide residues and calculated the number of hydrogen bonds between the
peptide and water. Figure 4.5 displays a snapshot of a typical frame that shows a singlefile water permeation between the outer and inner layers of the membrane. Movie S1
(Supplementary Information)72 shows how water molecules permeate across the bilayer
via hydrogen bonding with MU1140 residues. Single-filed hydrogen bonded chains of
water are often observed in nanoscale confinements such as in carbon nanotubes and
protein channels (e.g., the aquaporin gramicidin)109-110 and are of great interest because of
their unusual properties. As shown in Figure 4.5, water molecules in the single-file chain
region are considerably ordered, similar to the behavior observed in other biological water
channels such as gramicidin A111-112. The importance of the single-file water is underscored
by its role in transporting ions. In gramicidin A, the ability of single-file water to stabilize
K+ ions and transport it through the channel is due to the solvation of the ion by two single
file chains on either side113-114. Unlike fully non-polar carbon nanotubes, biological water
pores are lined with backbone carbonyl and amide groups that can form hydrogen bonds
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with water molecules. As here, water molecules in the single-file region predominantly
hydrogen-bond with carbonyl groups of MU1140 residues. With larger assembly of
MU1140-lipid II complexes, transport of cations may be possible because the polar lining
by the backbone carbonyl groups in MU1140 may form hydrogen bonding with
monovalent cations and facilitate ion transport as shown for epidermin and gramicidin115.

Figure 4.5 a) A representative snapshot of the water permeation along the MU1140 chain
(cyan) in the transmembrane region. Lipid II is shown in orange. b) Percentage of
hydrogen-bonding between MU1140 residues and water molecules, showing MU1140
hydrogen bonds with backbone CO (red), backbone NH (blue), and sidechain (SC) (green).
Only the phosphate atoms of the lipids are displayed for clarity.
The MU1140 structure inside the membrane shows a concaving at and below the
second thioether ring and this allows a proper orientation of CO and NH groups of MU1140
residues so that the water molecules can line along the chain (Figure 4.5a). I calculated the
% hydrogen bond between MU1140 groups and water molecules and plotted the results in
Figure 4.5b. Three residues Pro9, Ala11, and Ala16 are oriented away and make almost no
contacts with water. Since Phe1 and Asn18 are close to the bulk water, they are found to
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form most hydrogen bonds with water. While only the backbone groups of Phe1 are
involved in hydrogen bonding, Asn18 sidechain makes significant hydrogen bonding with
water. It is found that substitution of Phe1 with other resides does not negatively impact
MU1140 activity116,117 possibly because backbone hydrogen bonding is unaffected. Based
on the hydrogen bonding pattern, three different transmembrane regions can be observed
along the chain: 1) residues 1-5, 2) residues 6-13, and 3) residues 13-18. Along the
sequence Leu6 to Arg13, considerably ordered single-file water is observed. The MU1140
hydrogen-bonding with the single-file water is found to be with Leu6 (CO), Ala7 (CO),
Abu8 (CO), Gly10 (NH), and Arg13 (CO). Due to irregular ordering of backbone carbonyl
and amide groups, water passage below Ala12/Arg13 to the bulk occurs in a less ordered
fashion and can involve a sequence of as many as four water molecules hydrogen bonded
between Ala12 and Phe17. Due to the proximity to the bulk water, the Phe1 to Dhb5 as
well as Asn18 to HET21 have the water that is less ordered.

Figure 4.6 a) MU1140 orientation in the lipid bilayer along z-axis b) Representative
trajectories of successful water permeation across the membrane. c) A histogram of the
number of water molecules along z-axis is shown on the side.
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Significant water ordering and hydrogen bonding around the mid-region of the lipid
bilayer causes a longer residence times for the water molecules, with major bottlenecks for
the ion passage at Leu6 and Arg13. In Figure 4.6, I plotted the trajectory for a few
representative water molecules that successfully permeated along the z-axis across the lipid
bilayer. Water transport is observed in both directions. The concavity of the MU1140 in
the mid-region allows relatively more extensive hydrogen bonding for the water molecules.
I also plotted the histogram from all the successful trajectories (right panel), which shows
a significantly populated mid-region (left panel). This is consistent with the observations
in other biological systems which show markedly reduced diffusion of water with the
increase in hydrogen bonds with the pore-lining residues117. When the single-file water
molecules hydrogen bonds with the pore-lining residues, water movement is limited due to
the time it takes to not only break the hydrogen bonds but also to reorient and form new
hydrogen bonds while moving through the channel. In fact, Horner et al.117 found that the
flow of single-file water depends more on the number of hydrogen bonds with pore-lining
residues than the channel geometry. In contrast, the hydrophobic walls of carbon nanotubes
can allow unrestricted water flow109-110. In addition to the role of polar groups lining the
pore wall, water permeation across the membrane is also limited by the dehydration penalty
at the pore entrance. The fairly low population of water at the two extremes (i.e. |z|>15Å
in Figure 4.6) is likely due to this penalty. The two least populated regions (before Leu6
and after Arg13) represent the transition states for the water passage.
From the successful water permeation trajectories, I extracted the first passage
times for the water molecules to fully traverse the lipid bilayer. The mean first passage
time (MFPT) for the water molecule was found to be ~23 ns, giving a diffusion constant
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of D » 0.03 nm2/ns (i.e. 3 ´ 10-7 cm2/s) which is two orders of magnitude slower than the
water diffusion in nonpolar carbon nanotubes with D » 3 ´ 10-5 cm2/s.110, 118. Here, the
diffusion constant was calculated118 using 𝐷 = 𝐿" ⁄12〈𝑡〉, where L=2.8 nm is the channel
length and átñ = 23 ns is the first passage time. The diffusion constant is similar to the values
determined for other biological single file water channels such as aquaporin-1 (D » 4 ´ 107

cm2/s)117, and gramicidin (D » 3 × 10−7 cm2/s)119.

4.1.6 Water Permeation in Multimeric Assembly of MU1140-Lipid II Complexes
In many membrane binding and pore-forming amphipathic peptides, pore
formation occurs only if the peptide concentration exceeds certain threshold values120. In a
physiological environment, multiple MU1140 and lipid II molecules are likely to assemble
in the membrane. While nisin has 1:1 binding stoichiometry in solution121 , it is suggested
to form membrane pores with 2:1 ratio of nisin-lipid II assembly64. However, there is no
information available about MU1140-lipid II assembly. To investigate the multimeric
assembly of MU1140-lipid II and the behavior of water permeation, I set up additional
systems with two and four MU1140-lipid II complexes in the bacterial membrane. Both
systems were run for 500 ns each. For each set up, MU1140-lipid II complexes were placed
in the membrane with lipid II chains facing away from each other and MU1140 facing
towards each other (Figure 4.7). I observed that the MU1140 chains drifted towards each
other and water molecules permeated across the lipid bilayer. Movie S272 shows this
process for the four-chain system. In Figure 4.7, I highlighted (with red spheres) the water
molecules within 3.5 Å of MU1140 residues with red spheres. Before the simulation, only
a few water molecules above the upper lipid layer are in the vicinity of MU1140. At the
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end of the 500 ns simulations, both the two-chain system and the four chains systems show
significant water in the transmembrane region. Interestingly, the lipid molecules near the
MU1140-lipid II complexes were pulled inward. The four MU1140-lipid II complexes
show a significant shrinkage or distortion in the membrane thickness (Figure 4.7b, c). Due
to the short length of MU1140, the membrane is noticeably tapered near the MU1140-lipid
II assembly. This is also displayed by the number density of water molecules which shows
a narrowing of the density profile with the increase in the number of MU1140 chains
(Figure 4.7d). Figure 4.7d also shows a significantly higher population of water molecules
in the transmembrane region for the two and four complexes. An independent, additional
set of simulations for one, two, and four complexes yielded quite similar results of water
density profile as well hydrogen bonding pattern (Fig. S3)72. Here, the number density of
water molecules is calculated using the density profile plugin in VMD99 and represents the
number of atoms of water divided by the total number of atoms in the system projected
along the z-axis. The displayed number densities are obtained by averaging over the last
300 ns of the MD trajectories. The membrane distortion/tapering and lipid relocation
towards the central region of the lipid bilayer due to the MU1140 assembly in the
membrane suggests that a higher concentration of the peptide will cause significant
disruption of the bacterial membrane, and provides additional support to the model of
Matsusaki-Huang which previously proposed a membrane-thinning effect before the actual
poration process takes place for amphiphilic peptides.63
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Figure 4.7 Assemblies of a) two and b) four complexes of MU1140-lipid II in the bacterial
membrane at the beginning and end of the 500 ns simulations. MU1140 chains are colored
by residue types, lipid II chains are highlighted in yellow, and the water molecules within
3.5 Å of MU1140 are highlighted as red spheres. As in Figure 4.4, the phosphorus atoms
of POPE are shown as green spheres and POPG phosphorous atoms as gray spheres. c)
Same as b) but showing the water molecules above and below the lipid layers. The
membrane is tapered near the MU1140-lipid II assembly due to the short length of
MU1140. d) Density profile of the water molecules in the transmembrane region of the
lipid bilayer for one, two, and four complexes of MU1140-lipid II.
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For both the two and four complexes, significant hydrogen bonding between the
water molecules and MU1140 is observed as shown in Figure 4.8. For these complexes, I
calculated the percentage hydrogen bonding with water per chain and plotted the result as
a bar graph in Figure 4.8c. Compared to almost non-existent hydrogen bonding with Ala11
and Ala16 with in a single chain of MU1140 in the membrane, both the two and four chain
complexes showed markedly higher hydrogen bonding with these residues. Similarly,
Arg13 also showed an increased hydrogen bonding in the two and four MU1140-lipid II
complexes. Hydrogen bonding with other residues are found to be similar among systems
with one, two, and four complexes. Interestingly, the space between the two and four
MU1140 chains allows multiple water molecules to traverse the transmembrane region at
the same time, and thus breaks the single-file nature of the water permeation that occurs in
only chain (Figure 4.5). I calculated the first passage times for successfully traversing the
transmembrane region and plotted their distributions. It is interesting to note that the first
passage time distribution for one MU1140-lipid II complex has only one well-defined peak
with 〈𝑡〉=23 ns but the distribution for two and four complexes seem to show two different
timescales for the water traversing the lipid bilayer: 1) one peak around 22 ns, which is
similar to the one chain MU1140 system and likely represents the single-file transportation
and 2) the other peak at a much faster timescale ~10 ns, likely from the diffusion in the
mid-region.
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Figure 4.8 Representative snapshots of a) two and b) four MU1140-lipid II complexes
showing water permeation. MU1140 chains are shown in cyan color and lipid II chains
are shown in orange. For clarity, only the phosphate atoms of the lipids are displayed. C)
Percentage of hydrogen-bonding per chain for MU1140 and water in the transmembrane
region for one, two, and four complexes of MU1140-lipid II.

4.2 A Comparative Study of The Lipid II Binding and Transmembrane Properties of
Antimicrobial Lanthipeptides.
In this study, I use atomic-scale molecular dynamics (MD) computational studies
to compare both the lipid II binding ability and the membrane water channel formation
mechanisms and efficacy of five different lantibiotics that are part of the focus of current
antimicrobial research. They are nisin produced by Gram-positive bacteria Lactococcus
lactis122, Mutacin 1140 (MU1140) produced by Streptococcus mutans54, gallidermin
produced by Staphylococcus gallinarum123, NVB302 isolated from Actinoplanes
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liguriae124, and NAI107 , also known as microbisporicin or 107891, produced by the
actinomycete Microbispora125. Where, NVB302 and NAI107 are chemically modified
semi-synthetic lantibiotics125-127 (REF). Our results indicate that all five of these peptides
bind with the lipid II molecule, and also have the potential to form membrane water
channels however, the relative abilities vary dramatically. Among the five, nisin is found
to be the most effective water channel former. Gallidermin and MU1140 are found to bind
more strongly to lipid II molecules than the others. The shorter peptide NVB302 has the
interesting ability to taper the membrane bilayer which can lead to membrane disruption.
These detailed observations provide insight into the dynamics of membrane pore-forming
peptides6,
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and can facilitate the design and development of especially effective

antimicrobial agents.
4.2.1 Molecular Models of Peptide–Lipid II Complexes
Nisin is composed of 34 amino acids, NAI107 is composed of 23 amino acids,
MU1140 and gallidermin are each composed of 21 amino acids, and NVB302 is composed
of 19 amino acids (Figure 4.9). The crystallographic structure of the nisin-lipid II complex
was taken from the Protein Data Bank (PDB ID 1wco), and that of NAI107 was from PDB ID
2mh5. The structure of the MU1140-lipid II complex was taken from our earlier publication72.
This structure was used as a template to construct the 3D structure of NVB302-lipid II and
gallidermin-lipid II. Since the interaction region is the pyrophosphate moiety of lipid II, I used
a dipeptide (Ala, Glu) as a peptide moiety and a longer bactoprenol tail was used to provide a
stable anchorage during membrane-lipid II simulation. Figure 4.9 displays a schematic (left)
and 3D structure (right) of the five different peptide-lipid II complexes taken after 10 ns of MD
simulation in solution with no membrane.

46

NVB302

NAI107

Gallidermin

MU1140

Nisin

Figure 4.9 (Left) Schematic representation of the amino acid sequence for the lantibiotic
variants. (Right) Their modeled structure after a 10 ns MD simulation with lipid II (orange)
in solution, with no membrane.
The structures displayed in Figure 4.9 show that the number of saturated thioether
rings is three for gallidermin, three for MU1140, four for NVB302, four for NAI107, and
five for nisin. In common, MU1140, gallidermin, and NAI107 each have unsaturated
AviCys ring at the C-terminus. The net charge of these peptides, excluding N-terminus, is:
nisin (+3), MU1140 (+2), gallidermin (+2), NAI107 (0) and NVB302 (0). A net positive
charge helps a peptide to engage with the negatively charged bacterial membrane surface67, 104

. The positively charged nisin, MU1140, and gallidermin have a flexible hinge region

before the last two rings comprised of three, four, and four amino acids, respectively. That
flexibility helps them to insert into the bacterial membrane to form membrane pores. The
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neutral NAI107 is unique with the presence of a chlorinated TRP at residue 4 and a
hydroxyproline (HYP) at residue 14. The two neutral peptides NVB302 and NAI107 have
a more globular structure and hence it is of interest to investigate their behavior inside the
bacterial membrane.
4.2.2 Membrane Tapering
Previous studies63-64,

72, 128

demonstrated the pore forming ability of nisin,

gallidermin, and MU1140. For shorter lantibiotics like gallidermin, the pore formation
depends upon membrane thickness. However, there are no studies reporting on the pore
formation activities of Type B lantibiotics like NAI107 and NVB302. To investigate and
compare the mechanism of channel formation, I placed all five protein-lipid II complexes
vertically inside the membrane. Figure 4.10 shows snapshots of the initial and final
structures from the 500 ns simulation for each of the peptide-membrane system. For the
initial set-up, I exposed only the N-terminal to water, and I placed the C-terminal inside
the membrane. As the MD computations evolved, within the first 100 ns the C-terminal of
all peptides reached the other surface of the membrane and became exposed to water. This
spanning of the membrane allowed all five peptides to create a water channel (red spheres
in Figure 4.10). The shortest peptide NVB302, has an interesting mechanism for spanning
the membrane; it pulls the membrane surfaces inward towards each other so that less
distance is required of the peptide to span the membrane to expose both ends of the peptide
to water.
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Figure 4.10 Snapshot of the protein-lipid II membrane complexes: (left) initial set-up, and
(right) after 500 ns of MD computational simulation. The bacterial membrane is displayed
in gray and the gray spheres are the phosphate atoms on the two surfaces of the lipid
bilayers. Red spheres are water molecules within 5 Å of the peptides.
To quantify the membrane thinning caused by each peptide, we calculated the
average position of the phosphate atoms within 12 Å of the peptide on the upper membrane
surface, and the same for the phosphate atoms within 12 Å of the peptide on the lower
membrane surface. Figure 4.11 displays the separation of the membrane surfaces averaged
over the last 300 ns of the MD computational simulation. For reference, the control
thickness for the lipid bilayer without containing a peptide-lipid II complex is
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approximately 40 Å. It is observed that all the peptide complexes pull the membrane
surfaces inward. The thinning effect is least for MU1140 and gallidermin, moderate for
nisin and NAI107, and most pronounced for NVB302. Though nisin is the longest peptide,
it has quite a high membrane thinning effect. The presence of more hydrophilic residues at
the C-terminal region, especially the Lys residues, and absence of AviCys ring may
contribute to the pulling of the phosphate atoms. The pronounced squeezing of the
membrane by the shorter and globular lantibiotics NVB302, NAI107 assists their ability to
form membrane water channels once they insert into the membrane.

Figure 4.11 Membrane thickness Average distance between phosphate atoms of the top
and bottom of the membrane within 12 Å of peptides.
4.2.3 Channel Formation: Insertion and Transport of Water Across the Membrane
A. Water Insertion
Figure 4.10 shows that all the peptide-lipid II complexes form a water channel (red
spheres) through the membrane. To investigate the effectiveness of the membrane
channels, I calculated the number density of water molecules across the membrane along
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the lantibiotic peptide. The number density of water molecules was calculated using the
density profile plugin in VMD99, which calculates the concentration of water molecules
per length (Å) along a z-axis that is aligned along the peptide. Figure 4.4a is a density
profile of water molecules within the membrane region from z= -10 to +10 Å, averaged
over the last 300 ns of the MD simulation. This 20 Å segment of the channel spans the
membrane center that is at z=0. I chose to examine the water molecules along this inner
region of the channel’s z-axis because it avoids the piling-up of bulk water molecules at
the membrane surface. Figure 4.12 shows that the water number density at the center of
the channel is highest for nisin and lowest for gallidermin. It is interesting to see a relatively
high density of water for NVB302, even though it has the least number of residues. This
effectiveness in creating a channel may be related to the ability of NVB302 to significantly
taper the bacterial membrane, as seen in Figure 4.11. I also plotted the time evolution of
the number of hydrogen bonds formed by these lantibiotics with water molecules (Figure
4.12b). Consistent with its large water density, nisin has the highest number of hydrogen
bonds. Nisin is the longest of the peptides and has a more positive charge than the other
peptides. MU1140, NVB302, and gallidermin have approximately the same number of
hydrogen bonds. NAI107 has the least number of hydrogen bonds with water, possibly
related to its long, hydrophobic C-terminal tail.

51

Figure 4.12 For the protein-lipid II complexes: a) Density profile of the water molecules
along the z-axis of the transmembrane region of the lipid bilayer, b) During the last 300
ns of the MD simulation, the time evolution of the number of H-bonds made by each
peptide with water molecules.
B. Water Transport
Though the number density of water molecules is a good measurement for the
degree of water insertion inside the membrane, it does not directly measure the actual flux
of water molecules across the membrane. Hence, I also calculated the average number of
water molecules passing across the membrane from either side of the membrane during the
last 300 ns of the MD simulation. The results are plotted in Figure 4.13a. The relative
effectiveness of a peptide to enable water passage displayed in Figure 4.13a is
approximately the same as the relative effectiveness of allowing water insertion into the
membrane displayed in Figure 4.12a. Gallidermin has the least number of water molecules
(approximately 10) passing across the membrane. Figure 4.13a does not display any
notable directional preferences of water molecules passage through the membrane. I also
plotted the average passage time of water molecules across the membrane (Figure 4.13b).
For this calculation, I set the two ends of the membrane region to be at the z position of the
average position of the phosphate atoms of lipids in the lower and upper surfaces of the
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untapered membrane, which are z=-15 Å and z=+15 Å, respectively. Consistent with
nisin’s ability to allow water insertion into, and passage across the membrane, nisin also
displays the shortest time for water traversal across the membrane, which is further
evidence of the effectiveness of nisin in membrane channel formation.

Figure 4.13 For each of the peptide-lipid II complexes: a) Number of water molecules
passing across the membrane from either direction summed over the last 300 ns of the MD
simulation, b) Average passage time of a water molecule to cross the membrane region.
“Up” and “Down” refers to the average position of the phosphate atoms of lipids in the
lower and upper surfaces of the untapered membrane.
C. Peptide Hydrogen Bonding with Water
Especially important for single-file water transport across a membrane that is
facilitated by a single peptide is hydrogen bonding117, 129 between water molecules and
peptide amino acid residues. For each peptide, I determined the percentage of time during
the MD simulation that each residue makes a hydrogen bond with a water molecule. The
results are plotted in Figure 4.14. Since an amino acid can simultaneously make multiple
hydrogen bonds to multiple water molecules, the percentages can be greater than 100%. A
major contribution to hydrogen bonding for most residues in all the lantibiotics is from the
CO (red bars) and NH (blue bars) groups of the backbone. In addition, hydrophilic residues
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also display significant hydrogen bonding of water molecules with their side chain (SCgreen bars). The side chain hydrogen bonding is especially noticeable for nisin, which has
the largest number of hydrophilic residues in the interior of the membrane. It is also seen
that a peptide’s ability to draw water into the membrane (Figure 4.12a) and facilitate its
passage across the membrane (Figure 4.13a), is correlated with the hydrogen bonding
ability of the peptide (Figure 4.12b and Figure 4.14). Figure 4.12b and Figure 4.14 show
that nisin makes the most hydrogen bonds with water, and especially with hydrophilic
amino acids in the interior of the membrane. Figure 4.12a shows that this results in the
largest number of water molecules in the interior of the membrane, and Figure 4.13a shows
that nisin has the largest number of water molecules traversing the membrane. Figure 4.13b
also shows that nisin has the fastest passage time for water molecules across the membrane.
Thus, a strategic placement of hydrophilic residues along the peptide sequence can
facilitate water passage through the membrane.
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a) NVB302

b) MU1140

c) Nisin

d) NAI107

e) Gallidermin

Figure 4.14 Percentage of hydrogen-bonding between peptide residues and water
molecules, showing residual hydrogen bonds with backbone CO (red), backbone NH
(blue), and sidechain (SC) (green).
More details are given in Table 4.1, which provides a quantitative comparison of
the percentage contribution of the three groups (CO, NH, side chain) for all five
lantibiotics. Averaged over all peptides, the percentage contribution to hydrogen bonding
with water molecules from the backbone CO group is approximately 50%, with NAI107
having the lowest at 45%. The NH contribution averages 25% and is a maximum for
NAI107 at 31%. The side chain (SC) contribution to hydrogen bonding with water
molecules averages 25%, and is largest for nisin at 31%, which is expected because nisin
contains more hydrophilic residues than the other peptides.
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Lantibiotics

% contribution to H-bonds with water by
NH

CO

SC

Gallidermin

25

52

23

NAI107

31

45

24

MU1140

26

52

22

NVB302

22

49

29

Nisin

21

47

32

Table 4.1 Percentage contribution of peptide residues’ NH, CO, and SC hydrogen bonding
with water.
The correlation between hydrogen bonding and water passage is further displayed
by additional information contained in Figure 4.14 and Table 4.1. Figure 4.12a and Figure
4.13a show that gallidermin is least successful in drawing water into the membrane and
facilitating its passage. Figure 4.14 and Table 4.1 show that gallidermin is the only peptide
that has two different amino acids with less than 10% occupancy of hydrogen bonds,
PHE17(2%) and PRO9(6%). In contrast, nisin, which is most successful in drawing water
into the membrane and facilitating its passage does not have any amino acids with less than
10% hydrogen bond occupancy. The other three peptides have only one amino acid with
less than 10% hydrogen bond occupancy and their water passage facilitation falls between
gallidermin and nisin. Thus, just as large hydrogen bonding facilitates water passage
through the membrane, especially low hydrogen bonding by amino acid residues acts as a
roadblock to water passage. This is also seen in Figure 4.15, which displays for water
molecules that cross the membrane the average time that they spend near each residue (2.5
Å). The residues in Figure 4.14 that have especially small hydrogen bonding with water
lead to long delay times (bottlenecks) nearby, as seen in Figure 4.15.
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a) Gallidermin

c) MU1140

b) NVB302

d) Nisin

e) NAI107

Time spent by water molecules (ns)

Figure 4.15 Average time spent by water molecules near each residue (within 2.5 Å).

D. Water Passage Trajectories
Earlier studies suggested that other lantibiotics do not form pores as effective as
nisin because they are shorter and could not span the membrane63. Moreover, these studies
emphasize that the rigid, globular structure of some lantibiotics could be an especially big
hindrance to spanning the membrane and forming membrane pores59, 130. To study the
membrane-spanning ability of our five lantibiotics, I calculated the average structure of the
protein-membrane system from the last 300 ns of the MD simulation. The results are
displayed in the left column (I) in Figure 4.16. The upper and lower orange lines are drawn
at z = 10 Å and z = -10 Å, respectively. Outside of this region, I observed bulk water
molecules. The gray circles represent the phosphate atoms at the surface of the lipid
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bilayers. In the middle column (II), I plotted the trajectories of all water molecules that
successfully traverse the membrane during the last 300 ns of the MD simulation. Column
III (right panels) of Figure 4.16 display the density of successful water trajectories
projected onto the (x-y) plane.
Figure 4.16 shows that though the gallidermin and MU1140 both have 21 residues
and similar rings, MU1140’s amino acid sequence allows it to span the membrane while
gallidermin does not, which hinders water transport. There are relatively few successful
water trajectories for gallidermin and a relatively small region in the x-y plane that
successful water trajectories can navigate. A bend in the gallidermin structure at the
hydrophilic Lys13 residue prevents the peptide from elongating enough to reach the lower
leaflet and hence it functions poorly as a channel-forming peptide. In contrast, MU1140
contains the hydrophobic residue Trp4 in place of Lys4. The hydrophobic Trp4 is able to
easily assume different conformations in the hydrophobic environment inside the
membrane and therefore allows the C-terminal of MU140 to stretch to the lower surface of
the membrane. Among the two globular peptides, NVB302 forms more efficient channels
than NAI107, though both are capable of forming membrane channels via tapering the
membrane. Though NVB302 is the shortest of the peptides, it is the most effective at
tapering the membrane (Figure 4.11). Due to the wider cross-section of NVB302 around
the second and third thioether rings, it can provide multiple pathways for water molecules
to pass across the membrane (Column III). Nisin, the longest of the peptides, easily spans
across the membrane. Flexible kinks in the structure provide multiple paths for water
(Column II). Interestingly, Column III shows that nisin provides a reasonably wide number
of trajectories, but not the widest range of trajectories of the peptides. However, as seen in
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Figure 4.15, nisin has the fewest number of roadblock delay points along its structure. This
combination of a mid-level number of different trajectories along with no significant delay
points results in nisin being the most effective of the peptides in facilitating water transport
across the membrane.
Lys4
Lys13

Gallidermin

a)

z
y
y

x

x

b)
NAI107

z
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y
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x

MU1140

c)
Trp4
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y

Arg13
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x

x

d)
NVB302

z
y
y

x

x

e)
Nisin

z

y

y

x

x

Figure 4.16 For the last 300 ns of the MD simulation: Column I) Average position of
peptide (Cyan) and the phosphate atoms (gray) of the membrane surfaces. (II) Trajectories
of all water molecules that successfully cross the membrane (colors represent distinct water
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molecules). (III) Two-dimensional density plot along the x-y plane of the projection of the
trajectories in Column II.
4.2.4 Interaction with Lipid II
The water channel formation ability of lantibiotics discussed above may be a novel
mechanism involved with membrane disruption that can contribute to their bacteriostatic
or bacteriocidal properties. Another disruptive mechanism involves the interaction of a
peptide with lipid II molecules in the membrane. This mode of action requires the peptide
to first engage and bind with the pyrophosphate moiety of lipid II molecules before forming
membrane pores59, 65. To investigate this mechanism, I calculated the total energy of
interaction between peptides and lipid II molecules. The total energy is the sum of the
electrostatic interaction and Van der Waals interaction. Figure 4.17 shows that gallidermin
and MU1140 have the strongest total energy of interaction with lipid II molecules. NAI107
has the weakest interaction energy. Though nisin is the most efficient for transmembrane
water transport, its interaction with lipid II is notably weaker than that of gallidermin and
MU1140. I also calculated the number of hydrogen bonds made by these five peptides with
the pyrophosphate moiety of lipid II molecules during the last 300 ns of the MD simulation.
The results are plotted in Figure 4.17b and the ordering of the peptides is consistent with
the interaction energies of Figure 4.17a. Figure 4.17c depicts the important residues in
each peptide that make hydrogen bonds with the lipid II molecule.
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Figure 4.17 a) Total energy (Elec+VDW) of interaction between peptide and lipid II
molecule. b) The number of H-bonds made by each peptide with a lipid II molecule. c)
Important residues (blue) in each peptide that make hydrogen bonds with the lipid II
molecule (orange).
The graphs plotted in Figure 4.18 quantify the hydrogen bonding occupancy of the
residues highlighted in Figure 4.17 during the last 300 ns of the MD simulation. MU1140
has the highest occupancy with more than 60% for five residues (Lys2, Trp4, Abu8, Ala7,
and Phe1). The next is gallidermin with four residues (Ile1, Ala7, Lys4, Phe5) having more
the 60% bonding occupancy. NVB302 has two residues (Ser2, Trp4), nisin has three
residues (Ala7, Ile4, Ala3), and NAI107 has just one residue (5cw4) having more than 60%
hydrogen bonding occupancy. Figure 4.18 also shows that the NH group from the backbone
of these residues has the chief role in forming H-bonds with lipid II molecules. These
residues come from the first and second thioether ring of all the peptides that form the
binding cage for the pyrophosphate moiety.
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NAI107

Figure 4.18 Hydrogen bond occupancy percentage between lipid II molecules and the
peptide residues (for the last 300 ns of the MD simulation) highlighted in Fig. 4.17.
Hydrogen bonds with peptide backbone CO (red), peptide backbone NH (blue), and side
chain (green).
The results displayed in Figure 4.17 and Figure 4.18 show that even though
gallidermin is ineffective in facilitating water transport through the membrane, gallidermin
may be especially effective in disrupting cellular structure by interacting strongly with lipid
II molecules. This is also true for MU1140. In contrast, nisin is especially effective in
facilitating water transport, but interacts relatively weakly with lipid II.
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5. DESIGNING HYBRID LANTHIPEPTIDES FROM MUTACIN 1140 AND EBOLA
VIRUS DELTA PEPTIDE FOR IMPROVED DRUG PROFILE
Though there are many ways of managing the antibiotics resistance crisis, there is
an urgent and significant need for a new class of antibiotics to mitigate the threat of
antibiotic-resistance131. An important strategy to tackle resistant strains is to develop
therapeutic agents having multiple modes of inhibitory mechanisms132-134. Such multiaction or hybrid antibacterial agents provide advantages, including a broad range of
activity, difficulty for bacterial spontaneous mutation and resistance development, reduced
toxicity, and improved efficacy than 1+1 combinations of the individual constituent
agents135. Current hybrid antibiotics in research studies or clinical evaluations include the
super molecules formed by merging the features of two or more antibiotics, and
hybridization of antibiotics with non-antibacterial molecules134-138.
As described earlier, I explored the interactions of MU1140 with lipid-II and its
mechanism of membrane pore formation in the Gram-positive bacterial membrane using
molecular dynamics (MD) computational simulations. The MU1140-lipid II complexes
can form functional, water permeating membrane pores, and the anionic pyrophosphate
moiety of lipid-II provides the binding target for the first two thioether rings in MU1140.
The novel mode of action for MU1140 and other lantipeptides can potentially be exploited
to develop optimized peptide variants with improved antimicrobial properties and
therapeutic profile. However, the ability for membrane insertion of a peptide and
oligomeric pore assembly and stability in the hydrophobic transmembrane region comes
with a reduction in its solubility, thereby limiting the drug delivery and efficacy. In addition
to low solubility, also low production yield, proteolytic degradation, and susceptibility to
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oxidation are major limitations that decrease the druggability of lantibiotic peptides135, 139141

. The low production yield is mainly due to the elusive and cumbersome process of

synthesizing the AviCys moiety142-143, and it is a major hindrance for widespread usage139,
144

. Escano et al. in 2017, reported that the AviCys ring of MU1140 is necessary for the

lateral assembly mechanism of activity that traps lipid II into a large complex, and getting
rid of the ring reduces the bioactivity of the peptides. Their study suggested that the loss
of activity of the AviCys devoid variant MU1140-COOH can be restored by simple amine
capping143. Another excellent example of modifying the C-terminal for improved
antibacterial activity is in NVB302, which is currently under clinical trials12, 124.
In my study, in order to improve the druggability of MU1140, I modeled and
investigated hybrid antibiotic peptides combining notable features of MU1140 and the
EBOV delta peptide. In terms of membrane insertion and pore formation, the EBOV deltapeptide shares both structural and functional similarities with many other antimicrobial
peptides13, 145. The abundance of basic and aromatic amino acids and the disulfide crosslink at the C-terminal makes this peptide a membrane pore former. Addition of more
positively charged amino acids improves negatively charged membrane interaction and
enhances the solubility due to increased polarity. In addition, it can have a higher
production yield when the C-terminal AviCys ring is replaced with the conserved delta
peptide anchorage. It could be less prone to proteolytic degradation and oxidation because
the presence of a disulfide cross-link can improve the stability, as observed in other proteins
and peptides 101, 146.
To create hybrids, I used the front part of MU1140 and the back part of the EBOV
delta peptide, as seen in Fig. 5.1. Specifically, I selected the lipid-II binding segment
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composed of the N-terminus’ first 13 amino acids of MU1140 and three different length
sequences of amino acids from the C-terminal end of the EBOV delta peptide from
positions 22-40, 25-40, and 29-40. I connected the MU1140 13 amino acid segment’s Cterminus with the EBOV peptide segments’ N-terminus, thus producing three different
peptide models. I generated an additional three variants by introducing a single-point
mutation Glu33Arg. Hopefully, these peptides will have both the lipid II binding features
from the first two rings of MU1140 and the pore-forming ability from the C-terminal
amphipathic delta peptide. Using molecular dynamics simulations, I investigated these
peptides to evaluate their druggability. Our study shows that the longest hybrid peptide
containing residues 22-40 from the EBOV delta peptide with negatively charged Glu33
stands out among the other five with regard to the overall assessments of solubility, binding
affinity with lipid II molecules, membrane insertion, and pore formation ability. Such a
detailed study may be helpful in designing better antimicrobial drugs and unravel new
pipelines of hybrid chemical entities with the combination of antibiotics and other poreforming viral and antimicrobial peptides.
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MU1140

EBOV Delta Peptide

S

a)

b)

Phe Lys Ala
Trp

Pro Gly
Ala Ala Arg Cys Thr Val
Ala Abu
Lys
Leu
Glu
S
Dha
S
Lys
Cys Gln Leu
Arg
Ile
S

Pro Gly
Ala Ala Arg Gln Trp Phe Lys Cys Thr Val
Ala Abu
Lys
Leu
Trp
Glu
S
Dha
S
Lys
Cys Gln Leu
Arg
Ile

Phe Lys Ala

S

c)

29-40
(S, SM)

25-40
(M, MM)

Pro Gly

Phe Lys Ala

Ala Abu
Leu
Trp
Dha

S

Ala Ala Arg Ile Pro Leu Gln Trp Phe Lys Cys Thr Va
Lys
l
Glu
S
Lys
Cys Gln Leu
Arg
Ile

22-40
(L, LM)

Figure 5.1 Hybrid model from MU1140 and the EBOV delta peptide with possible
mutation. a) The shorter models S and SM. b) Medium models M and MM. c) Longer
models L and LM. The mutated models SM, MM, and LM are from mutating Glu33
(orange star) with Arginine.
5.1 Modeling the Hybrid Structure
The structures of MU1140 and the EBOV delta peptide were taken from our
previous studies29, 72. MU1140 has 21 amino acids, and the delta peptides contain 40 amino
acids (Figure 1.1). To build the hybrid peptide, I included the first 13 amino acids from
MU1140, which includes all the amino acids from the lipid II binding cage and the charged
amino acid Arg13 essential for membrane interaction and water channel formation. From
the EBOV delta peptide, I took three different amino acid segments of different lengths
from the C-terminal end. The shorter model (S) includes the residues from 29-40 (Figure
5.1a), the medium model contains residues from 25-40 (Figure 5.1b), and the longer model
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(L) contains residues from 22-40 (Figure 5.1c) from the EBOV delta peptide. I also
modeled the same peptides but with a single point mutation of negatively charged (at
neutral pH) Glu33 substituted with positively charged Arg33, named SM, MM, and LM,
respectively. The wild-type MU1140 is denoted as WT. The total number of amino acids
and their charges in all variants are shown in Table 5.1. All of the hybrid variants have a
higher fraction of polar and charged residues than WT.
Variants

Polar
Residue
%
43

Charged
Residue %

Total
Charge

WT

Total
Residue
No.
21

10

2

L

32

44

22

5

LM

32

44

22

7

M

29

48

24

5

MM

29

48

24

7

S

25

48

24

4

SM

25

48

24

6

Table 5.1 Total number of residues and fraction of polar and charged residues of modeled
structures
5.2 Solubility Assessments
Aqueous solubility of a drug is a major factor determining its bioavailability, a key
to its effectiveness147-148. Poor solubility is one of the most common obstacles that prevent
many newly discovered chemical entities to reach the market149-150. Drug solubility
depends on various factors such as the polarity of the drug and the solvent, size of the drug,
temperature, and pH of the solvent

151-152
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. Though hydrophilicity influences the

disaggregation and dissolution of drugs in solution, a soluble polar molecule may lack
lipophilicity for drug permeation, and also suffer screening due to ionic charges in the
solution153. Hence, pharmaceutical research focuses on modeling and optimizing novel
amphipathic agents with a proper fraction of hydrophilicity and hydrophobicity, or
combinations with functionalized groups or carriers for effective drug delivery148, 154-155.
To examine our modeled structures' solution behavior, I performed molecular
dynamics simulations for 500ns for each peptide in an explicit water system. Figure 5.2a,
shows the initial (left of arrow) and final snapshots of the MD trajectories. The blue and
red spheres represent the N and C-terminal carbon atoms. All peptides collapse to globular
structures, and continue to expose their polar (blue and green licorice structures) and
charged residues to the water. To investigate the size and the flexibility of the peptides, I
calculated the radius of gyration (RGYR) from the last 200 ns of the MD production run
using a VMD plugin and display the results in a box plot in Figure 5.2b. The box plot
depicts the median (center line), mean (blue star), and the fluctuations of RGYR. The
average RGYR is the highest for the LM peptide and is the least for the WT, M, and S
variants. LM also has the highest RGYR fluctuations. Interestingly, the L variant has a
significantly smaller average RGYR than LM, and the L variant has the smallest RGYR
fluctuation of all variants. All the variants with Glu33 have smaller average RGYR and
smaller fluctuations than the mutated variants with Arg33. The conformational flexibility
in monomeric form can be linked to a peptide's solubility: the more flexible the peptide,
the less likely it is to form a hydrophobic cluster or aggregate. However, other structural
and dynamical factors such as intra-peptide hydrogen-bonding, surface area-to-size ratio,
fluctuation in the hydration layer, and the abundance of charged residues may govern the
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a)

b)

500 ns

500 ns

500 ns

500 ns

SM

M

500 ns

MM

S

LM

L

WT

solubility148, 156-157.

500 ns

500 ns

Figure 5.2 a) Snapshots of peptides form the initial (left of arrow) and final frames of 500
ns MD trajectories. The blue and red spheres represent the N and C-terminal carbon
atoms. The blue and green licorice structures represent the charged and polar amino acids
while the white color represents the hydrophobic amino acids. b) Box plot of the average
radius of gyration (RGYR) form the last 200 ns of the MD production run. The blue star
represents the mean value.
From the last 200 ns of the simulation, I also calculated (Table 5.2) several
parameters related to the peptide variants' solubility, including the number of hydrogen
bonds (H-bonds) with water and the solvent accessible surface area (SASA) using the
VMD plugin. I also calculated the average number of water molecules within 2.5 Å of the
peptide, representing the water molecules in the first hydration layer, which is responsible
for the interactions with the peptides. In Fig. 5.3, I plotted the data for the hydrogen bonds,
average number of water molecules, along with the number fluctuation (Hy-fluctuations),
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and the SASA. The plot has a relative vertical scale, with the largest value for each category
normalized to 100% for better comparison. Table 5.2 shows that the H-bonds for the first
three peptides WT, L and LM have a maximum hydrogen bonding of around 38 (converted
to 100% in Fig. 5.3), suggesting better solubility for these peptides. The LM peptides have
the a much higher water fluctuation in the first hydration layer than the other two, and the
WT has the smallest water fluctuations of all the peptides. The WT also has the smallest
hydrophilic SASA and smallest hydrophobic SASA of all peptides due to its short length
(Table 5.1) and compact configuration (Fig. 5.2). The hydrophilic SASA is maximum for
the MM peptide. Based on comparison of the hydrogen bonds with water and the
hydrophilic SASA, it is expected that the solubility of L, LM models is comparable to WT.
Also, more hydrophilicity or the number of charged residues might lead to a better
solubility.

Variants

No. H-bonds
with water

Hydration
Fluctuation

RGYR
(Å)

Hydrophilic
SASA
(Å2)

Hydrophobic
SASA
(Å2)

WT
L
LM
M
MM
S
SM

38.4
38.2
38.5
35.4
36.9
29.8
31.1

6.2
9.1
15.3
10.5
10.1
13.2
12.7

8.9
10.0
11.6
9.1
10.5
9.0
9.7

412.6
553.4
604.8
526.6
647.8
489.1
563.4

493.7
694.3
804.5
632.3
647.4
564.4
535.2

Table 5.2 Various parameters measured from averaging over the last 200 ns of the MD
production run of the WT and hybrid variants.
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Figure 5.3 Normalized plot of various parameters from Fig. 5.2: H-bonds (number of
hydrogen bonds of peptide with water molecules), Hy-fluctuation (fluctuation of water
molecules in first hydration layer of peptides, SASA-philic (SASA of hydrophilic amino
acids), and SASA-phobic (SASA of hydrophobic amino acids).
Accurately predicting the solubility of a peptide using MD observables is a
complicated task and a more rigorous statistical and thermodynamic approach is needed to
predict the solubility of peptides, especially the lanthipeptides composed of modified
amino acids and sulfur bonds. Still, these hybrid peptides possess increased hydrophilicity
and hydrophobicity than the WT, and this may lead to improved druggability of the
peptides.
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5.3 Lipid II Interaction
Binding to the lipid II molecule and hindering its function in cell wall biosynthesis
is a major mechanism of action for lantibiotics. Notably, the shorter lantibiotics like
gallidermin have strong binding affinity with lipid II63. In addition to the lipid II binding
moiety, the C-terminal tail of the peptide plays a role in binding and sequestering lipid II
into large lipid II-lantibiotic clusters143.
To investigate the peptide interactions with the lipid II molecule, I prepared
peptide-membrane systems for the six variants by placing them on the bacterial membrane
surface, along with a lipid II molecule (Figure 5.4a). For each system, I performed 1µs of
MD simulation.

72

Figure 5.4 a) Snapshot of L variant initially placed at the surface of the membrane, and
after 1 μs of MD simulation. The brown molecules are lipids in the membrane and the
brown spheres are phosphate atoms of lipids in the membrane surface. For all six variants,
the time evolution of: (b) number of hydrogen bonds, and (c) interaction energies between
the peptide and lipid II molecules.
Figure 5.4b shows the time evolution of the number of hydrogen bonds between
each of the variant peptides with lipid II molecules. Initially, the L model forms
approximately four hydrogen bonds that changes to approximately six at the end of 1µs.
The hydrogen bonding in LM is stable throughout the simulation with approximately five
hydrogen bonds. The S variants shows the weakest binding to the lipid II molecule with
the least number of hydrogen bonds. Based on the hydrogen bonding, L and LM models
appear to have a better lipid II binding affinity than WT variant, which forms
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approximately four hydrogen bonds with lipid II on the membrane surface in 500 ns
simulation time scale (Figure 4.2c)72. To compare the interactions for the variant peptides,
I plotted the total interaction energy (electrostatic + van der Waals) calculated using the
VMD module in Figure 5.4c. The interaction energy also shows the same pattern as the
hydrogen bonding, with higher number of hydrogen bonds resulting in lower, stronger
energy of interaction. The L variant shows a better binding with minimum energy and the
S variant with highest energy at the end of 1µs. Compared to the other variants, LM shows
better overall interactions with lipid II, whereas M has the least fluctuations in the
interaction with the lipid II molecule. The largest number of hydrogen bonds between lipid
II molecules and the peptides are made with five mutacin amino acids that are common to
all of the variants. In Fig. 5.5, I plot the number of hydrogen bonds to each of these amino
acids, averaged over the last 300 ns of the MD simulations. The backbone nitrogen atoms
of these residues play a dominant role in the hydrogen bonding.
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a)

d)

b)

c)

e)

f)

Figure 5.5 Percentage occupancy of hydrogen bonds between peptide amino acids and lipid
II, averaged over the last 300 ns of 1 µs MD run for each variant: (a) L, (b) LM, (c) M, (d)
MM, (e) S, (f) SM.
5.4 Membrane Insertions
In addition to the lipid II binding, other properties of the peptides such as membrane
insertion, water pore formation, and disruption of the bacterial membrane are needed for
the lantibiotics to possess dual modes of action. Therefore, the designed peptide models
are desired to have a better or comparable membrane insertion profile compared to the WT.
Insertion of a peptide using regular MD computations can require a time that is too long to
be feasible. To quantify the insertion profile energetically, I performed steered molecular
dynamics (SMD) computations and pulled the backbone carbon-alpha atoms of the
residues Glu33, Lys34, and Leu35 (numbering based upon their positions in the Ebola delta
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peptide) of the peptides through the bacterial membrane bilayer at a constant velocity of
0.5 Å/ns. For the mutated variants, Arg was substituted for Glu. Figure 5.6a displays the
initial and final configuration of a peptide pulled through a membrane.
I calculated the magnitude of the pulling force along the negative z-axis and plotted
it in Figure 5.6b. The z-coordinate represents the center-of-mass of the backbone carbon
atoms from the three residues that are pulled. The membrane spans a region from -20 Å
(lower, inner leaflet) to + 20 Å upper, outer leaflet). The graph shows that it requires an
increasing force to pull the peptide variants through the membrane until the three pulled
amino acids cross out of the lower leaflet of the membrane.

Figure 5.6 a) Pictorial representation of the SMD constant velocity pulling through the
membrane of backbone carbon atoms of three amino acids at the tail of variant L. b) Force
required to pull at constant velocity across the z-coordinate of the membrane. The two
dotted vertical lines define the upper and lower boundaries of the lipid bilayer.
The trajectory of conformations during the SMD pulling of the peptides through
the membrane allow further investigations by calculating the potential of mean force
(PMF) using MD umbrella sampling and free energy profiles. For the umbrella sampling,
I took 25 different conformations having the center-of-mass of the carbon atoms of the
three pulled residues from z = 19 Å to z = -29 Å, giving 25 windows separated by 2 Å. For
each window, I performed MD sampling simulations of 10 ns. I used the WHAM tool to
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sample free energy values from the MD trajectories across various windows and plot the
results in Figure 5.7. The graph shows that WT and M insertion are the most energetically
favorable compared to other variants, followed by the L variant. The plot shows that the
free energy is the most unfavorable for LM, MM, and S insertion into the membrane.

Figure 5.7 Free energy of pulling of peptides across the membrane.
In my previous work, I reported that despite having a significantly shorter chain
compared to nisin, WT (MU1140) could span the transmembrane region and create a
channel for water permeation72. To study the degree of spanning across the membrane and
water channel formation of the six new variants, I placed them across the membrane along
with a lipid II molecule (Figure 5.8a). I placed the N-terminal of a variant at the upper
leaflet and the C-terminal at the lower leaflet of the membrane. From 1 µs MD simulations
for each variant, I observed water permeation across the membrane, sliding along the
peptides for all models. Figure 5.8a shows the initial and final snapshots of the 1 µs
trajectory for L. To quantify the water insertion behavior for each peptide, I located the
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average position of all water molecules along the z-axis within 5 Å of the peptide from the
last 300 ns of the trajectory. In Fig. 5.8b, I plot the probability density profile for water
molecules. For the shorter models S and SM, the bottleneck region is found to be around z
= 10 Å, and for all others, it is around z = 5 Å. The non-zero density profile suggests that
all of these peptides are capable of forming an effective water channel. The expanded
region in the inset shows that the L peptide is the most efficient at the bottleneck.

Figure 5.8. Water transport through the membrane. a) Initial and final snapshots of the L
peptide place across the membrane. The red spheres denote the water molecules within 5Å
of the peptide. b) Probability density, averaged over the last 300 ns of the MD simulation,
of water molecules within 5 Å of peptides placed across the membrane.
Figure 5.8b also shows the degree of water ‘funneling’ by peptides outside the lipid
bilayer. The extent of water funneling is represented by the left and right peaks of the water
probability densities in the graph. Though L and LM have the same number of residues,
the L model funneling extends more than the LM model, and other shorter peptides have
correspondingly shorter funneling profiles. More polar residues in the C-terminal account
for the higher density peak on the left side (lower layer) than on the right side (upper layer).
5.5 Membrane-Pore Formation
As I observed the L and M models are energetically favorable for membrane
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insertion, I was interested to see if they can form oligomeric membrane pores, similar to
Nisin and Mutacin as reported in recent studies64, 72. Using a custom script, I modeled the
pentameric pores for both variants by placing the corresponding monomers symmetrically
with an average initial radius of approximately 6 Å. The pentameric oligomer was chosen
based on the pentameric pore formation by the Ebola virus delta peptide29. I inserted the
pore model into the bacterial membrane and ran the MD simulation for 500 ns. Figure 5.9a
and Figure 5.9b show the initial and final snapshots of the MD trajectories for the pores of
L and M peptides. I observed that the L model's C-terminal constitutes transmembrane
alpha-helix, while the M model mostly has a loop or disordered structure. Figure 5.9c and
Figure 5.9d show that both pore models are effective at water transport across the
membrane. I also calculated the water density profile using density profile tools99. Each
density profile is a one-dimensional density calculated along the pore's z-axis and averaged
over the last 300 ns of the MD trajectory. The graph in Figure 5.9e represents the density
of water in terms of the number of water molecules/Å3. This plot also demonstrates that
both models can form equally efficient water channels across the bacterial membrane.
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a)

c)

d)

500 ns

e)

b)

500 ns

Figure 5.9 Initial and final snapshot of MD trajectories of pentamer pore of L (a) and M
(b). Water transport across the membrane by pores of L (c) and M (d) model. e) Number
of water molecules/Å3 projected along z-axis within the membrane region of L and M
pentameric pores.

In Figure 5.10, I have quantified the size and stability of pores from the MD
trajectories using HOLE program95. This program computes the volumetric map and
transverse radius of pores based on the van der Waals radius of the peptide atoms. Figure
5.10a and Figure 5.10b are the 3D visualization pore size for initial and final frames of L
and M models from 500 ns production run. Sections that are too narrow to pass any water
molecules would be colored red, green if they allow one water molecule to pass, and blue
if they are wide enough to pass two or more water molecules. I observed two different
bottlenecked regions; the L model has narrower restriction at the N-terminal region while
M has that around the C-terminal region. In Figure 5.10c displayed the pore radius along
the channels' z-axis during the final 300 ns along with the standard deviation. The midpoint of the membrane is chosen to define z=0. In both pores, the average radius of the
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pores is higher than 2.5 Å, giving a diameter greater than 5 Å, which is significantly larger
than the diameter of a water molecule, 2.8 Å. The L model has a minimum average radius
around z = 10 Å, while the M model has a wider minimal range from z = -5 to z = 5 Å. L
model has a narrower deviation below z = 10 Å, indicating that the C-terminal helical
structure contributes to forming stable and smooth membrane pore. Figure 5.10d displays
the time evolution of root mean square deviation (RMSD) for 500 ns MD run with
reference to initial model. The L model changes its configuration slowly, and after 350 ns,
it becomes stable. While there is an abrupt change in the M model configuration during the
first 100 ns of MD run, and it becomes stable after that. At the end of 500 ns, the L model's
deviation is slightly lower, showing that it retains a more symmetric initial configuration
than the M model.
b)

a)
500 ns

c)

500 ns

d)

M

L

Figure 5.10 Volumetric map of pentameric pores of L (a) and M(b) models. c) Average
radius of pores from last 200 ns. d) Time evolution of root mean square deviation of pore
structures of L and M models.
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6. CONCLUSIONS
The EBOV delta peptide is a viroporin peptide that forms homo-oligomeric pores in the
membrane. In this work, I modeled various delta peptide oligomeric pores of different
numbers of peptides and systematically explored the pore stability, ion selectivity, and the
role of the peptide disulfide bond using all-atom molecular dynamics simulations in an
explicit lipid bilayer. I considered tetrameric, pentameric, and hexameric peptide
assemblies of the EBOV delta peptide for membrane pore formation. Molecular dynamics
simulations showed that the pore formed by the tetrameric assembly of the peptide is not
stable. For the simulated timescales I studied, both pentameric and hexameric assemblies
formed stable, ion-permeable membrane pores that selectively permeate water and chloride
ions across the lipid bilayer. The pentameric pore is slightly more stable than the hexameric
pore. Compared to the other oligomeric assemblies, the pentameric assembly allows a
tighter packing of the adjoining helices, providing stronger van der Waals interactions as
well as the two H-bonds that stabilize the pore. These interactions are weaker in the
tetramer and hexamer. The pore radius, ion density and flux profiles show that the EBOV
delta peptide pores may have directional selectivity for permeating chloride ions. In
addition, our results show that the conserved disulfide-bond formation between Cys-29 and
Cys-38 in a delta peptide is essential for pore stability and ion flux.
Overall, our computational study suggests that: (1) the EBOV delta peptide likely
forms stable pentameric pores in the membrane bilayer, (2) the viroporin is selective in
allowing a passage of chloride ions but prevents passage of sodium ions, and (3) the
conserved intra-peptide disulfide-bond is essential for a pore’s stability as well as for ion
flux. These findings lead to future investigations to study the role of membrane
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composition158 and peptide concentration on pore formation as well as the energetic factors
governing ion selectivity through the pores. Further studies with multiple replicas of
various constructs as well as biophysical analyses are needed to ascertain the exact nature
of the oligomeric assembly of delta-peptide in the membrane. Detailed understanding of
the mechanisms of pore formation by delta peptide may lead to the design and development
of targets for pore modulators and disruptors, and thus the ability to control virus
propagation.
Another membrane-pore forming peptide I investigated is the antimicrobial peptide
MU1140. The ability of MU1140 to bind to the lipid II pyrophosphate moiety in a
membrane and abduct it from the septum of division, therefore obstructing bacterial cell
wall synthesis, makes it a promising antimicrobial candidate for antibiotic-resistant
pathogens.
The bacterial-killing mechanisms of certain antimicrobial peptides can be complex
and involve more than a single mode of action. For example, it can include interference of
the lipid II function and membrane pore formation or membrane disruption. Interestingly,
it has been suggested that the lantibiotic spectrum of activity and potency is not necessarily
related to the numbers of mechanisms involved. Bonelli et al.63 previously reported that
epidermin and gallidermin are 10-20 times more potent against Lactococcus lactis than
nisin, despite the missing pore formation capacity on that strain. In addition, it was
previously shown that the [A12L] gallidermin variant is as active as wild-type gallidermin
against Micrococcus flavus, despite losing its pore-forming activity.63
Peptides that have similar moieties and structural features as MU1140, including
nisin, epidermin, and galidermin, have been shown to possess the dual functions in several
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bacterial strains. However, the molecular mechanisms of how MU1140 and its variants
interact with lipid II or form the permeable membrane pores have only been inferred from
the structural similarities with nisin and gallidermin. In this work, I explored the
interactions of MU1140 with lipid II as well as the mechanism and sequence of membrane
pore formation by the MU1140-lipid II complexes in a Gram-positive bacterial membrane
using MD simulations. As with nisin, the anionic pyrophosphate moiety of lipid II provides
the binding target for the thioether rings in MU1140. The formation of a stable MU1140lipid II complex highlights the lipid II trafficking mechanism of MU1140 suggested by
experimental studies61, 159-160.
Despite structural differences in the C-terminal tail as well as peptide length
between nisin and MU1140, our results show that MU1140-lipid II complexes are able to
form functional, water permeating membrane pores. Even a single chain of MU1140
complexed with lipid II is able to permeate water molecules across the membrane via a
single-file water transport mechanism, which is commonly observed in nanoscale
confinement such as carbon nanotubes and protein channels. The ordering of the water
molecules in the single-file chain region as well as the diffusion behavior is similar to those
observed in other biological water channels such as gramicidin A. Multiple complexes of
MU1140-lipid II in the membrane showed enhanced permeability for the water molecules,
as well as noticeable membrane distortion and lipid relocation towards the central region
of the lipid bilayer. The results suggest that a higher concentration of MU1140 assembly
in the membrane can cause significant disruption of the bacterial membrane. These
investigations, for the first time, provide an atomistic level insight into a novel mode of
action for MU1140. Further biophysical investigations with different variants of MU1140,
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lipid compositions, and multimeric assemblies can provide important insights for the
rational design of optimized peptide variants with improved antimicrobial properties.
Ribosomally synthesized and post-translationally modified lantibiotics are potent
antimicrobial compounds that exert their action against Gram-positive bacteria via a dual
model of action, including having a unique binding site to lipid II molecules. Studies have
found that variants of some of these lantibiotics are effective against resistant strains such
as methicillin-resistant Staphylococcus aureus (MRSA) and clostridium difficile infections
(CDI)53, 161. I investigated five lantibiotic variants: nisin, MU1140, gallidermin, NAI107
and NVB302. Using atomic-scale molecular dynamics computations, I examined the
ability of these five different peptides to participate in two different anti-bacterial
mechanisms: facilitate water transport across a membrane, and to form bonds to lipid II
molecules.
My study shows that all of these five lantibiotics are able to form water transport
channels across the membrane, but the efficiency of the channels differs widely. Nisin
forms the most effective membrane channel that passes the largest number of water
molecules per unit time. Though nisin provides a reasonably large number of different
trajectories through the membrane for water transport, it is not the widest range of
trajectories of the peptides. However, nisin’s water trajectories have the fewest number of
roadblock delay points along the length of the channel. This combination of a mid-level
number of different trajectories, along with no significant delay points results in nisin being
the most effective of the peptides in facilitating water transport across a model membrane.
Therefore, a strategic placement of hydrophilic residues along the peptide sequence may
facilitate water passage through the membrane, although this remains to be confirmed
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experimentally. However, this benefit from hydrophilic amino acids must be delicately
balanced by the effect of hydrophilic amino acids on the ability for the peptide to insert
into the hydrophobic membrane interior, which requires further investigation. I found that,
though gallidermin and MU1140 have the same number of amino acids, the presence of
Lys4 and Lys13 in gallidermin prevents it from spanning the membrane and greatly
diminishes gallidermin’s ability to transport water. The shortest peptide, NVB302,
facilitates a mid-level of water transport. NVB302 accomplishes this by pulling the
membrane surfaces inward towards each other. This makes the membrane thinner and
allows the short NVB302 to span the tapered membrane.
Though gallidermin was the least effective in facilitating water transport across the
membrane, it is very effective at forming hydrogen bonds to lipid II molecules, along with
MU1140. Therefore, gallidermin’s ability to kill bacteria may better correlate to its strong
binding to lipid II and impeding the critical functioning of lipid II in bacterial cell wall
biosynthesis, rather than forming membrane pores. MU1140 is reasonably effective at both
mechanisms. In contrast, nisin is especially effective in facilitating water transport, and is
known to allow ion transport as a “true” pore-former but makes a relatively small number
of hydrogen bonds with lipid II. The globular lantibiotics, NVB302 and NAI107, are
similar to MU1140 in that they are moderately effective in both facilitating water transport
and in forming bonds to lipid II molecules. These investigations provide atomistic insight
to the mechanism of water channel formation and lipid II interaction of these five
lantibiotic peptides. These studies provide insight that can guide the design of novel
antibiotics.
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The dual modes of antimicrobial activity: 1) blockage of peptidoglycan synthesis
by binding to and abduction of lipid II and 2) membrane pore formation ability, makes
lantibiotics promising candidates for antibiotic-resistant pathogens. However, the poor
solubility, low production yield, and susceptibility to degradation by digestive enzymes are
major challenges encountered for oral administration and widespread uses of lantibiotics.
In this work, I showed that by creating hybrid peptides composed of lantibiotic segments
with the combination of an EBOV delta peptide segment, we can improve at least some of
these challenges. The hybrid peptide models contain the lipid II binding cage of MU1140
and the conserved C-terminal transmembrane amphipathic helix from the EBOV delta
peptide. From the molecular dynamic simulations, I assessed various factors which can
determine the druggability of these models. I found that the longer models provide more
charged amino acids and better hydrophilicity than WT, and hence might have better
solubility. The overall lipid II binding affinity is best for the LM hybrid during our
simulation time scales evaluated by the energy of interaction and hydrogen bonding with
lipid II. On the other hand, SMD force and free energy analysis from MD umbrella
sampling indicate that the membrane insertion profile is energetically favorable for L and
M models. These L and M models form efficient pentameric membrane pores, though the
pore from the L model is slightly more stable and smoother than from the M hybrid.
In summary, the L model has a better profile among the six hybrid variants, and its
hydrophilicity, hydrophobicity, and lipid II binding profile are even better than MU1140.
The L variant, having a amphipathic transmembrane helix, not only forms a more efficient
membrane pore, it is also less likely to be degraded by proteolytic enzymes due to
conserved disulfide bonds as observed in many peptide and proteins. Finally, the major
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advantage of this hybrid structure could be the high production yield due to the absence of
an AviCys ring. Though experimental procedures should be performed to verify these
computational results and speculations, this study proposed a new peptide scaffold for
efficient therapeutics against antibiotic resistance via numerous permutations of
lantibiotics and transmembrane peptides.
7. OVERALL SUMMARY
Membrane-permeabilizing peptides evolve for offensive or defensive purposes as viral
peptides, host-defense peptides, venom, or toxins. Viral peptides function as a viroporin
and form pores in the host cell in both bacterial and Eukaryotic membranes for the primary
purpose of replicating and propagating viral particles100, 162-163. Structural and dynamical
studies of such viroporins is essential for the development of antiviral drugs that could
interfere with the pore functionality and hence the propagation of viruses18. Host-defense
antibacterial and antiviral peptides disrupt the bacterial membrane and viral envelopes164168

. These antimicrobial peptides are a plausible candidate for the development of novel

antibiotics. Discovery of novel antibiotics, especially those with novel mechanisms of
action, is critical to mitigating the threat of antibiotic-resistance169. Antibiotics containing
lanthionine, referred to as lantibiotics170, constitute a promising class of drugs to battle the
threat of antibiotic resistance.
The Ebola virus (EBOV) is a filamentous lipid-enveloped virus that causes severe
hemorrhagic fever with a high fatality rate in humans171. The EBOV encodes a
glycoprotein that when cleaved, produces the delta peptide. Experimental evidence
suggests that the delta peptide functions as a viroporin that enhances virus particle release
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through the host cell membrane20, 30. However, the viroporin forming mechanism of the
delta peptide is still not well understood. Guided by experimental information, I have
computationally investigated the pore formation by different oligomers of the delta peptide.
I have performed all-atom molecular dynamics (MD) simulations in an explicit membrane
environment to investigate the pore-forming mechanism and stability of the pores. The
results suggest that the delta peptide forms stable pentameric pores. In addition, the pore is
selective with respect to chloride ions, and the disulfide bond formed between Cys-29 and
Cys-38 in the C-terminal of the peptide is essential for the pore stabilization and ion
permeation. This study provides helpful information on the pore-forming mechanism of
filovirus delta peptides and such structural information can be important in designing and
developing molecular modulators that target the delta peptide pore and disrupt the
pathology of the Ebola virus.
Lantibiotics are ribosomally synthesized peptides that contain post-translationally
modified unusual amino acids102, 130. Lantibiotics are promising candidates to engage in the
fight against resistant strains of bacteria due to their unique modes of action12. It is proposed
that the antimicrobial activities of Lantibiotics are attributed to two modes of action: 1)
vancomycin-like blockage of the peptidoglycan synthesis by binding to and abduction of
lipid II and 2) membrane pore formation61, 64, 172-173. One such variants, Mutacin 1140
(MU1140) produced by Streptococcus mutans54 is a promising antimicrobial lanthipeptide
and is effective against Gram-positive bacteria. I explored the potential mechanisms of
Lipid II binding and membrane pore formation by performing molecular simulations of the
MU1140-lipid II complex in the bacterial membrane. My investigation suggest that
MU1140-lipid II complexes are able to form water permeating membrane pores. I find that
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a single chain of MU1140 complexed with lipid II in the transmembrane region can
permeate water molecules across the membrane via a single-file water transport
mechanism. The ordering of the water molecules in the single-file chain region as well as
the diffusion behavior is similar to those observed in other biological water channels.
Multiple complexes of MU1140-lipid II in the membrane showed enhanced permeability
for the water molecules, as well as a noticeable membrane distortion and lipid relocation,
suggesting that a higher concentration of MU1140 assembly in the membrane can cause
significant disruption of the bacterial membrane.
In another study, I use atomic-scale molecular dynamics (MD) computational
studies to compare both the lipid II binding ability and the membrane water channel
formation mechanisms and efficacy of five different lantibiotics that are part of the focus
of current antimicrobial research. They are nisin produced by Gram-positive bacteria
Lactococcus lactis122, Mutacin 1140 (MU1140) produced by Streptococcus mutans54,
gallidermin

produced

by

Staphylococcus

gallinarum123,

NVB302

isolated

from Actinoplanes liguriae124, and NAI107 , also known as microbisporicin or 107891,
produced by the actinomycete Microbispora125. Where NVB302 and NAI107 are
chemically modified semi-synthetic lantibiotics125-127. I find that all five of these peptides
bind with the lipid II molecule, and also have the potential to form membrane water
channels. However, the relative abilities vary dramatically. Among these, nisin is found to
be the most effective at permeating water across the membrane. Compared to other
variants, Gallidermin and MU1140 are found to bind more strongly to lipid II molecules.
The shorter peptide NVB302 has the interesting ability to taper the membrane bilayer
which can lead to membrane disruption.
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Lantibiotic Mutacin 1140 (MU1140) has shown a broad spectrum of activity
against Gram-positive bacteria, including Clostridium difficile infection11, 174. However,
poor aqueous solubility, susceptibility to proteolytic degradation, and low production yield
of lantibiotics are significant hindrances for their bioavailability, especially for oral
administration and cost-effective commercial production139-140, 143, 175. The preferable way
to address those challenges could be the hybridization of these peptides with other peptides
to improve the overall drug profile134-136, 138. In this work, I explored the hybridization of
MU1140 and Ebola virus (EBOV) delta peptide to design the potential antimicrobial
chemical entities. Our result suggests that among various hybrid variants the L model,
constitute of 1-13 amino acids from MU1140 and 22-40 amino acids form EBOV delta
peptide, shows better profile in term of solubility, binding with lipid II molecule, bacterial
membrane insertion, and pore formation mechanism. These thermodynamical
investigations could be useful for the design and development of potential antimicrobial
entities by hybridizing lantibiotics with other pore-forming viral and antimicrobial peptides
to address poor drugability of lantibiotics to mitigate the threat of resistant bacteria.
A future direction could be to design a ligand molecule that can bind with the Ebola
virus pentameric pore and hinder the pore function.

Among five variants that I

investigated, the lantibiotic MU1140 is equally effective for lipid II binding and membrane
channel formation. Hence, the future focus should be on investigating variants of MU1140
from single or multiple point mutations of amino acids. Insight into the lipid II binding,
water-solubility, membrane insertion, and pore formation could help develop a novel
molecule with optimized bactericidal properties. Among the hybrid variants that I
investigated, L and LM variants' solubility and lipid II binding profiles were the best. On
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the other side, M has the lowest free energy for membrane insertion. Therefore, it is
worthwhile to investigate the hybrid molecules having amino acids sequences between L
and M models in the future.
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